



**EVER 2005**

**P R O G R A M M E**

Vilamoura, Portugal • October 5 - 8, 2005


[www.ever.be](http://www.ever.be)

21 CME credits



# Endurance

TRAVATAN® Solution is still going strong 24 hours post dose.<sup>1\*</sup>



**TRAVATAN®**  
(travoprost eye drops solution 0.004%)  
**Control That Lasts.**

#### Prescribing Information

**TRAVATAN®** (travoprost eye drops solution). **Presentation:** Oval polypropylene bottle containing 2.5 mL eye drops. One mL of solution contains 40 micrograms of travoprost (0.004% w/v) and benzalkonium chloride 0.15 mg. **Indication:** Decrease of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma who are intolerant or insufficiently responsive to another intraocular pressure lowering medication, as monotherapy or adjunctive therapy. **Dosage and Administration:** Adults including the elderly: The dose is one drop in the conjunctival sac of the affected eye(s) once daily. Optimal effect is obtained if the dose is administered in the evening. *Children and adolescents:* Not recommended. *Use in hepatic and renal impairment:* No dosage adjustment is necessary. **Contraindications:** Hypersensitivity to travoprost or any of the excipients. **Precautions:** TRAVATAN® may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes. Before treatment is instituted, patients must be informed of the possibility of a permanent change in eye colour. Unilateral treatment can result in permanent heterochromia. Macular oedema, including cystoid macular oedema, has been reported during treatment with prostaglandin F<sub>2α</sub> analogues. Exercise caution in patients with known risk factors for macular oedema. Periorbital and/or eyelid skin darkening in association with the use of TRAVATAN® has been reported in 0.6% of patients. As with other prostaglandin analogues, TRAVATAN® may gradually change eyelashes in the treated eye(s). These changes include increased length, thickness, pigmentation, and/or number of lashes. Since TRAVATAN® contains benzalkonium chloride, close monitoring is required with frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised. Patients must remove contact lenses prior to application of TRAVATAN® and be instructed to wait 15 minutes after instillation of TRAVATAN® before inserting contact lenses. **Interactions:** Interactions with other medications have not been specifically evaluated. **Side Effects:** The most frequently reported side effect is ocular hyperaemia. Other side effects include: Common (1% to 10%): ocular pruritus, ocular discomfort, ocular pain, dry eye, foreign body sensation, iris discoloration, photophobia, cells, keratitis, flare and headache. Uncommon (0.2% to <1%): tearing, blurred vision, conjunctivitis, eyelash lengthening, ocular irritation, iritis, lid oedema, sticky sensation, conjunctival follicles, decreased visual acuity, blepharitis, browache, conjunctival papillae, hypotension, bradycardia and periorbital skin discoloration. **Overdosage:** If overdosage with TRAVATAN® occurs, treatment should be symptomatic. **Special Precautions for Storage:** No special precautions for storage. Discard 4 weeks after first opening. **MA Number:** EU/1/01/199/001-002. **MA Holder:** Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead, Herts, HP2 7UD, UK.

\* A washout period of 4 weeks was followed by 2 weeks of TRAVATAN® Solution (n=16) or latanoprost monotherapy (n=18). At day 14, the final dose was administered at 8 PM and IOP measurements were taken. Baseline values for the two treatment groups were not significantly different. The standard deviations for the TRAVATAN® group were 3.9 mm Hg (12 hours), 2.9 mm Hg (16 hours), 3.2 mm Hg (20 hours), and 2.1 mm Hg (24 hours). For the latanoprost group, the standard deviations were 3.8 mm Hg (12 hours), 3.0 mm Hg (16 hours), 3.2 mm Hg (20 hours), and 3.1 mm Hg (24 hours). The difference between the two groups at 24 hours post dose was statistically significant (p=0.0117).

#### Reference

1. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. *Clin Ther.* 2004;26:84-91.



## a word from the president


Dear Colleagues,

The aim of EVER is to bring together all those in Europe and neighbouring countries who are taking part in research on the Eye and Vision. This year the Annual meeting of EVER begins on Wednesday 5th October with two scientific workshops which will take place in the afternoon. We will finish on Saturday 8th October and as usual poster prizes will be presented for each section. The prizes will be awarded at the beginning of the Annual General Meeting on Saturday 8th October. As before the structure of the meeting will consist of Special Interest Symposia, Keynote Lectures, Free Papers, Posters, Workshops and Courses and accreditation for the meeting has been arranged with the CME authorities.

This year we are returning to Vilamoura in Southern Portugal with its excellent conference facilities and ease of access.

An important development since last year has been the forging of links with ARVO and you will see that Professor Kaufman is representing the American society, which has had a great influence on the formation of our own.

On behalf of all those involved in the organisation of the meeting I welcome you to join us for the exchange of ideas in very pleasant surroundings.



Nick GALLOWAY

EVER President 2005

## About EVER...

EVER, the European Association for Vision and Eye Research, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange activities.

### Membership

Membership is open to individuals of any nationality engaging in or having an interest in ophthalmic and vision research who meet the requirements established by the EVER Board. To become a member, a candidate shall apply to the General Secretary on the membership form. The application must be endorsed by one member and the applicant shall pay an application fee. If the candidate does not know any member who can endorse his/her application, he/she should attach a letter explaining the situation. The candidate becomes a member upon recommendation by the EVER Board and upon payment of the dues. The meetings of EVER are open to members and non members. However, only members and candidate members can submit material for a presentation.

Any group within EVER may organise symposia, workshops or other activities within a meeting. Any proposal should be sent to the Programme Secretary or to the scientific section representative before the end of the preceding year.

### Elections

This year new representatives of the scientific sections **Neuro-ophthalmology** and **Oncology / Pathology** will be elected through electronic voting. The result of the elections will be announced at the General Assembly on Saturday.

The scientific sections will hold their Business Meetings on Friday from 19:00 till 19:30. The sections on **Immunology / Microbiology** and on **Physiology / Biochemistry / Pharmacology** will nominate candidates for the succession of their representatives in the Board of EVER. The statutes and by-laws are available on the website: [www.ever.be](http://www.ever.be) » about » statutes



## BOARD

### Executive Committee

President	N Galloway, Nottingham
Secretary General	J Jonas, Mannheim
Treasurer	P Aydin, Ankara
Programme Secretary	A Churchill, Bristol
Past president	P Söderberg, Stockholm
President Elect	T Kivela, Helsinki
Vice-president	F Van der Werf, Rotterdam
Vice-president Elect	A Safran, Geneva
Co-opted	JJ De Laey, Gent

### Chair of sections

Anatomy / Cell Biology	E Knop, Berlin
Cornea / Ocular Surface	H Dua, Nottingham
Glaucoma	S Orgul, Basel
Immunology / Microbiology	U Pleyer, Berlin
Lens and Cataract	R Michael, Barcelona
Molecular Biology / Genetics / Epidemiology	M Votruba, Cardiff
Neuro-ophthalmology / Strabismology	A Safran, Geneva
Pathology / Oncology	T Kivela, Helsinki
Physiology / Biochemistry / Pharmacology	I Haefliger, Basel
Retina / Vitreous	Ch Riva, Sion
Vision Sciences / Electrophysiol. / Physiol. Optic	G Holder, London

### Regional Representatives

G Maraini, Parma  
G Hollo, Budapest

### Local Organisers

J Cunha-Vaz, Coimbra  
R Proenca, Coimbra

### EVER Office

Kapucijnenvoer 33  
B-3000 Leuven, Belgium  
Tel. +32 – 16.233.849  
Fax +32 – 16.234.097  
[marlene.verlaeckt@ever.be](mailto:marlene.verlaeckt@ever.be)  
[www.ever.be](http://www.ever.be)

## Location

EVER 2005 will be held in the **Marinotel** in Vilamoura, Algarva, Portugal from Wednesday October 5 till Saturday October 8, 2005.

The **scientific programme** begins on Wednesday at 14:00 and concludes Saturday at 19:00. The **EVER Welcome Party** starts on Wednesday at 19:00 and is open to all registered participants.

## Registration

Everyone attending the scientific sessions—whether or not an EVER-member, invited speaker, accompanying person or presenter—must register and pay the registration fee.

The pre-registration deadline is September 1, 2005. At any time, you can register and pay your registration fee on-line at [www.ever.be](http://www.ever.be) using your credit-card. If you do not register on-line, you can still register on-site in Vilamoura starting from Wednesday at 12:00.

Please note that

- being or becoming an EVER-member or having an abstract accepted does not imply that you are registered: all first authors must register
- if you register as a member in training, you need to prove your traineeship by showing a document signed by the Head of your Department
- if you register for OOG-only, you cannot attend other scientific sessions
- if you register as an accompanying person, you are not allowed to attend the scientific sessions
- Refunds—up to 75% of the registration fee—will be granted for cancellation, received in writing, prior to September 20, 2005. Refunds will not be granted for later cancellation or no-shows.

## Registration fees after September 1, 2005

EVER-member or SIS-invited speaker	310 EUR
Member in training	160 EUR
Non-member	490 EUR
Non-member in training	245 EUR
Course	30 EUR
OOG-only (no access to other sessions)	100 EUR
Accompanying person	105 EUR

## Website

The EVER website [www.ever.be](http://www.ever.be) has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2005 meeting
- pay on-line and obtain an overview of past payments
- view the status (session, hour, place) of your presentation
- look for other EVER-members
- get general information about EVER
- go to useful links
- express your vote



## Travel

Vilamoura can be reached in less than 20 minutes from Faro Airport. Because the Algarve is a popular tourist destination, there are many flights to Faro airport, either direct or via Lisbon.

## Transportation

A **shuttle bus** will operate between Faro airport and Vilamoura on Wednesday (08:00 – 21:00), Saturday (19:00 – 21:00) and Sunday (06:00 – 12:00). Price for a single trip is 10 EUR. Taxis are also available at the airport.

## Weather

Vilamoura has an exceptional climate and offers sun all year round. Average temperature in October is around 23° Celsius, with about 10 hours of daily sun.

## Tourist information

Vilamoura is the name of an area rather than a town. It covers about 2000 hectares of land, partly with vegetation, partly with forests. Thanks to the size of the resort area, it offers every visitor nearly every form of sport and entertainment: four different golf courses, a large marina, a lawn bowling club, a tennis centre, sports club, shooting club, tourist apartments, night clubs, international casino, cinema and riding school. In the center of Vilamoura, there is a preserved Roman site and Museum of Cerro da Vila. In the neighbourhood of Vilamoura, there is the small fishing village called Quarteira and the commercial and administrative town of Loulé.



# Information about the meeting of 2005

## Social programme

The social programme is open for all participants and registered accompanying persons.

On Wednesday, there is the EVER Welcome Party, in the Marinotel.

On Saturday, the EVER Farewell dinner takes place in the garden of the Marinotel.

## Coffee

Coffee and soft drinks are provided, free of charge, during the meeting from 09:30 till 12:30 and from 15:00 till 17:30.

## Internet access

There is a Business Center in the Marinotel.

## Scientific programme access


You can visit [www.ever.be](http://www.ever.be) for the most up-to-date scientific programme. A CD-ROM—sponsored by Alcon—is included with this programme book. All abstracts will be published in Volume 37, Supplement 1, 2005 of Ophthalmic Research. This abstract book will be available on-site in Vilamoura.

## Poster prizes, sponsored by the AER

A poster prize of 100 EUR will be awarded for the best poster in each section. The winners will be chosen by the moderators and will be announced in the General Assembly meeting on Saturday October 8<sup>th</sup>, 2005.

## Awards 2005

We are pleased to announce that the following 3 researchers have received travel award from the 'Tear Film and Ocular Surface Society' for the best 3 abstracts submitted to EVER 2005 by young researchers in the cornea section: Min CHANG, Jean-Louis BOURGES, Elizabeth SZLITER.



## PC Data projection

A single beamer for pc-projection is provided in each hall. This is a modern beamer that can handle all conventional resolutions, although a standard resolution of 1024x768 pixels is recommended. The beamer cannot be used at the same time as the video projection.

EVER provides a modern pc (Office XP / Windows XP, English version) in each hall, so you do not have to bring your own laptop. Bringing your laptop with you is discouraged, not only because of theft risks (especially at airports) but also because of the hassle of branching this machine between presentations. We prefer your presentation on a CD, DVD or memory stick. ZIP-drives are not allowed.

Please try to stick to standard Microsoft Powerpoint presentations. Other presentation programs (Apple Keynote, Corel Presentations, Staroffice / OpenOffice) can be used of course, but there is always a small risk involved.

You can check the projection in the AV Support room, a few hours before your presentation. Hand in your CD / DVD / memory stick to our technical staff. They will assist you to solve any compatibility problem you might encounter.

If you really insist on using your own laptop for whatever reason, please make solid arrangements with our technical staff. 30 minutes before the start of the session you must bring your laptop to the lecture hall. You should start your computer programme before the session begins, to prevent delay between presentation. Time lost while fumbling with the computer will not be compensated.

Upon request and after arrangements with our technical staff, Apple Macintosh computers can be used. Do not forget to bring your own connector cables: modern Apple Powerbooks often use "DVI" (digital) output ports, which need a small cable to convert DVI to standard VGA (analog). Apple iBooks often need a special cable as well to be branched to a beamer.

## Video projection

A videoplayer with support for both VHS and SVHS (but no long-play VHS) is provided. It reads PAL (European) video cassettes.

Please note that the video projection cannot be used simultaneously with pc (Powerpoint) projections.

Check your video in the slide reception room before your presentation. Video's which have not been announced and checked at the slide reception room cannot be shown. Please contact our technical staff to make sure everything will work as expected.

**Slide projection is no longer supported.  
Please use Powerpoint instead.**

## Posters

The poster exhibition takes place in **Room: Neptuno**. Each poster is exhibited for one day only. You should install your poster in the morning between 08:00 and 09:00 and remove it the same day after 19:00. EVER is not responsible for any poster left behind at the end of the day.

You will find the number of your posterboard in one of the poster sections of this programme book (at the end of each day). The size of the posterboards is 190 cm wide x 100 cm high (landscape orientation).

You should ensure that you are standing beside your poster during the poster session. On Thursday and Friday from 16:30 to 17:30, on Saturday from 15:30 to 16:30. During this time moderators and EVER participants will be voting which poster should win the poster prize.

## Withdrawals

First authors unable to attend EVER for reasons beyond their control, may request permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 20, 2005.

Please note that any first author whose paper is not presented without a valid excuse, once it has been accepted, will be prohibited from presenting papers at EVER for the next two years.





*ever 2005*

**Wednesday 5 October**



## COURSE I

Gemini III		<b>Electrophysiology in inherited disease</b>	14:00 – 17:00
Graham HOLDER, Bart LEROY, Colin BARBER			
14:00	1321	Basics of testing and ISCEV Standards HOLDER GE–London	
14:40	1322	The application of electrophysiology to a genetic eye disease practice LEROY BP–Ghent	
15:20		<i>Break</i>	
15:40	1323	Multifocal ERGs BARBER C–Nottingham	
16:20	1324	Diagnostic electrophysiology in inherited disease HOLDER GE–London	
17:00		<i>End</i>	

## COURSE II

Vega		<b>Appropriate use of ancillary and new imaging methods in the appraisal of intraocular inflammatory diseases</b>	14:00 – 17:00
Ahmed ABU EL ASRAR, Bahram BODAGHI, Carl P HERBERT, Marc D DE SMET			
<i>Introduction by CP Herbert</i>			
14:00	1341	Principles and practice of fluorescein angiography ABU EL ASRAR AM–Riyadh	
14:20	1342	Principles and practice of indocyanine green angiography (ICGA) HERBERT CP–Lausanne	
14:40	1343	Ultrasound biomicroscopy (UBM) in inflammatory diseases HERBERT CP, TRAN VT–Lausanne	
14:55	1344	Ocular coherence tomography (OCT) in inflammatory diseases DE SMET MD, VAN VELTHOVEN MEJ, VERBRAAK FD, ROSEN R–Amsterdam, New York	
15:15	1345	Uveitic macular edema: quantitative assessment by OCT and correlation with visual acuity ABU EL ASRAR AM, AL TURKI RH, AL KARASHI AS, AL KURAYA HS–Riyadh	
15:30	1346	Radiology and Ultrasound in uveitis BODAGHI B–Paris	
15:50	1347	The role of imaging reading centers in clinical studies PETO T, LEUNG I, HARRIS N, KHATUN M, MOLDON I–London	
16:05		<i>Break</i>	
16:20		<i>Illustrative cases and discussion</i>	
17:00		<i>End</i>	

Please remember that you need to register separately if you want to participate in a course.

**Welcome**

17:00 – 17:15  
Fenix III

***Welcome by the President Nick GALLOWAY***

Nick GALLOWAY — President EVER 2005

**AER Lecture**

17:15 – 18:00  
Fenix III

***Evolution of Cataract Surgery, Corneal Transplantation and Refractive Surgery***

Joaquin BARRAQUER—Barcelona

Introduction by Gijs F.J.M. VRENSSEN

**EVER Lecture**

18:00 – 18:45  
Fenix III

***A little bit of light on the lens***

Per SÖDERBERG—Stockholm

Introduction by Nick GALLOWAY

**Social Activity**

19:00 – 21:00  
Marinotel garden

***EVER Welcome Garden Party***



*ever 2005*

**Thursday 6 October**



Gemini I		<b>Free papers : Molecular Biology / Genetics / Epidemiology 1</b>	08:30 – 10:00
FP		Jochen GRAW, Marcela VOTRUBA	
08:30	2111	Four families with recurrent erosions as the main symptom but with four different phenotypes FAGERHOLM PPP, HAMMAR B, DELLBY A–Linköping	
08:42	2112 <i>rf</i>	Homozygote cyokeratin 12 mutation in a Danish family with Meesmann's dystrophy NIELSEN KN, ORNTOFT TFO, HJORTDAL JH, EHLERS NE–Aarhus	
08:48	2113	Single Nucleotide Polymorphisms in Vascular Endothelial Growth Factor gene and their Association in patients with Age-Related Macular Degeneration CARTER JG, LOVELL HC, RAMSDEN C, TURNER SJ, YEUNG A, ESCARDO J, CHURCHILL AJ–Bristol	
09:00	2114	Awareness of Adult Refsum's Disease as a cause of retinitis pigmentosa: a survey of UK ophthalmologists SHAMS PN, DAVIES NP, GIBBERD FB, WIERZBICKI AS, FEHER MD–London	
09:12	2115 <i>rf</i>	Study of Primary Mutation and Clinical Features of Leber's Hereditary Optic Neuropathy in Chinese Patients GUO X, WANG Y, JIA X–Guangzhou, China	
09:18	2116	A family with autosomal dominant optic atrophy and cataract (ADOAC) and an electronegative ERG VOTRUBA M, DAVIES VJ, THISELTON D, HOLDER G, MOORE AT–Cardiff, Richmond, VA, London	
09:30	2117	Characterisation of a new mouse model for retinoschisis DALKE C, JABLONSKI M, FAVOR J, PRETSCH W, GRAW J–Neuherberg, Memphis	

Gemini III		<b>Eye Banking</b>	08:30 – 10:00
SIS		Ilse CLAERHOUT	
08:30	2121	Introduction KESTELYN PH–Gent	
08:30	2122	Organ culture PELS E, MAAS H–Amsterdam	
08:45	2123	Hypothermic storage (2-6 degrees Celsius) ZANETTI E–Venice	
09:00	2124	Assessment of the endothelial cell density and morphometry during corneal storage: what do we measure and how? THURET G, ACQUART S, GAVET Y, GARRAUD O, GAIN P–Saint-Etienne	
09:15	2125	Immunological aspects of banking CLAERHOUT I–Ghent	
09:30	2126	Influence of new lamellar techniques on eye bank activity MURAINÉ M–Rouen	
09:45		<i>Discussion</i>	

Pegasus		<b>Free papers : Physiology / Biochemistry / Pharmacology 1</b>	08:30 – 10:00
FP		Nicholas DELAMERE	
08:30	2131	Effect of Bimatoprost, Latanoprost, PGF2a, Travoprost and Unoprostone in Quiescent Isolated Human Ciliary Arteries ALLEMANN RA–Basel	
08:42	2132	First report on a prostaglandin-ethanolamide (prostamide) receptor antagonist AGN 204396 STRUBLE C, WOODWARD DF, KRAUSS AHP, NIEVES AL, PROTZMAN CE, WANG JW, BURK RM, DONDE Y, LANDSVERK K–Madison, WI, Irvine CA	
08:54	2133	Polymorphism of the b-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects FUCHSJÄGER-MAYRL GF, MARKOVIC OM, LOSERT DL, LUCAS TL, SCHMETTERER LS–Vienna	
09:06	2134	Effects of topical clonidine and brimonidine on choroidal blood flow and intraocular pressure during isometric exercise WEIGERT G, RESCH H, GARHOFER G, SCHMETTERER L–Vienna	
09:18	2135	The influence of carbonic anhydrase inhibitors on cytoplasmic pH in nonpigmented ciliary epithelium DELAMERE NA, TAMIYA S, MATHEWS SA, HOU Y–Louisville, KY	
09:30	2136	Retinal Morphology after Intravitreal Administration of Erucylphosphocholine in an in-vivo Rat Model EIBL KE, SCHUETTAUF F, SHINODA K, MAY CA, WELGE-LUESSEN UC, KAMPIK A–Munich, Tuebingen, Dresden	

Vega	<b>Retinal pigment epithelium</b>	08:30 – 10:00
SIS	Hannu UUSITALO	



08:30	2141	Wellcome to RPE SIS UUSITALO H–Kuopio
08:35	2142	Lipofuscinogenesis and lysosomal dysfunction of RPE TERMAN A, BRUNK UT–Linköping
08:55	2143	Regulatory role of heat shock proteins in the ubiquitin proteolytic pathway in RPE cells KAARNIRANTA K–Kuopio
09:15	2144	Barriers and mechanisms of non-viral gene delivery into retinal pigment epithelium URTTI A–Kuopio
09:35	2145	RPE repair and transplantation: the challenges for the future BOULTON M–Cardiff
09:55		Concluding remarks

Fenix I	<b>Emerging agents and novel aspects in inflammatory eye diseases</b>	08:30 – 10:00
SIS	Luca CIMINO, Carl P HERBORT	

08:30	2151	Introduction : emerging agents and novel aspects in inflammatory eye diseases HERBORT CP–Lausanne
08:35	2152	Neglected and unrecognized signs in Fuchs' uveitis HERBORT CP, BOUCHENAKI N–Lausanne
08:50	2153	Tuberculous uveitis, a re-emerging cause of uveitis CIMINO L, HERBORT CP, SALVARANI C, BOIARDI L–Reggio Emilia, Lausanne
09:05	2154	Ocular lesions in rickettsial and West Nile virus infections KHAIRALLAH M
09:25	2155	New manifestations of ocular herpetic diseases BODAGHI B–Paris
09:40	2156	How to manage and diagnose intraocular inflammatory oddities DE SMET M–Amsterdam
09:55		Discussion

Fenix III	<b>Extraocular muscles, new observations and clinical implications</b>	08:30 – 10:00
SIS	Richard BRUENECH, Fatima PEDROSA DOMELLOF, Avinoam SAFRAN	

08:30	2161	Characterization of the human extraocular muscles at the cellular and molecular level PEDROSA DOMELLOF F, KJELLGREN D, THORNELL L-E–Umeå
08:50	2162	The role of innervation in the development of extraocular muscles PIEH C–Freiburg
09:10	2163	Sensory receptors in extraocular muscles (EOM) and their potential role in oculomotor control HAUGEN I-B K, BRUENECH JR–Kongsberg
09:30	2164	The structural organization of the distal insertions of human extraocular muscles (EOM) BRUENECH JR, KJELLEVOLD HAUGEN I-B–Kongsberg

**Keynote Lecture**

10:15 – 10:55  
Fenix III

**Ocular surface regeneration: Present and Future**

Shigeru KINOSHITA—Kyoto  
Introduction by Harminder DUA



Gemini I		<b>VEGF – from gene to therapy</b>	11:00 – 12:30
SIS		Amanda CHURCHILL	
11:00	2211	Inhibitory VEGF isoforms in Diabetic Retinopathy BATES DO–Bristol	
11:20	2212	Molecular therapies for ocular neovascularisation ALI R–London	
11:40	2213	Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age-Related Macular Degeneration (SANA) Study MICHELS S, SCHMIDT-ERFURTH U, ROSENFELD PJ–Vienna, Miami	
12:00	2214	A Phase II Randomized, Double-masked Trial of Pegaptanib, an Anti-Vascular Endothelial Growth Factor Aptamer for Diabetic Edema ADAMIS A–New York	
12:20		Discussion	

Gemini III		<b>Corneal Wound Healing</b>	11:00 – 12:30
SIS		Jean-Jacques GICQUEL, Paul Louis DIGHIERO	
11:00	2221	Corneal wound healing and blood derived growth factors DIGHIERO PLD–Poitiers	
11:10	2222	Amniotic Fluid and Ocular Surface Disease BEHRENS A–Baltimore, MD	
11:20	2223	Ocular surface defense and innate immunity KINOSHITA S–Kyoto	
11:30	2224	AMT benefits on corneal wound healing DUA HS, HOPKINSON A–Nottingham	
11:40	2225	Early AMT in severe bacterial keratitis: our 2 years experience GICQUEL JJ, ELLIES P, MERCIE M, DIGHIERO PL–Poitiers	
11:50	2226	The potential of hair follicle stem cells in corneal reconstruction BARRANDON Y	
12:00	2227	Scleral Contact Lenses in the management of Ocular Surface disorders MURAINÉ M, DELCAMPE A, LAROCHE JM, DOAN S, HOANG XUAN T, BRASSEUR G–Rouen, Paris	
12:10	2228	Corneal wound healing and growth factors RIECK P–Berlin	

Pegasus		<b>Free papers : Physiology / Biochemistry / Pharmacology 2</b>	11:00 – 12:30
FP		Einar STEFANSSON, Leopold SCHMETTERER	
11:00	2231	Retinal oximetry: Comparison of data from two centers HARDARSON SH, KARLSSON RA, HALLDORSSON GH, KAGEMANN LE, RECHTMAN E, ZOEGA GM, EYSTEINSSON T, BENEDIKTSSON JA, THORSTEINSSON A, BEACH JM, HARRIS A, STEFANSSON E–Reykjavik, Indianapolis, IN	
11:12	2232	Altered retinal blood flow regulation in response to hyperoxia during experimental endotoxemia in healthy humans POLSKA E, KOLODJASCHNA J, SCHMETTERER L–Vienna	
11:24	2233	Breathing of 100% oxygen does not alter the response of retinal vessels to stimulation with flicker light GARHOFER G, WEIGERT G, RESCH H, SCHMETTERER L–Vienna	
11:36	2234	Local retinal venous reaction to monochromatic flickering light in normal volunteers of different age KOTLIAR KE, VILSER W, MÜCKE B, LANZL IM–Munich, Ilmenau	
11:48	2235	Effects of latanoprost and timolol on oxygen saturation in retinal vessels in healthy humans BALEANU D, LÄMMER R, SCIBOR M, HARAŻNY J, MICHELSON G–Erlangen	

Vega	<b>FRO 1</b>	11:00 – 12:30
Joint M.	Marie - José TASSIGNON	

11:00	2241	To correlate the level of plasma VEGF family members with the exudative form of age-related macular degeneration SOHNGEN P
11:20	2242	To correlate two major health problems, obesity and age-related macular degeneration, through the leptin, by animal and human studies BLAISE P
11:40	2243	Chlamydia psittaci and chromosomal abnormalities in ocular adnexal MALT Lymphoma DECOCK C
12:00	2244	Human lens capsule allotransplantation to replace Bowman's membrane of the cornea ACAR Z

Fenix I	<b>Changing concepts in inflammatory eye diseases</b>	11:00 – 12:35
SIS	Ahmed ABU EL ASRAR, Carl P HERBORT	

11:00	2251	Introduction ABU EL ASRAR A–Riyadh
11:05	2252	Experimental uveitis : introducing a new model TERRADA C, SALOMON BL, BODAGHI B–Paris
11:20	2253	New concepts in the classification of choroiditis HERBORT CP–Lausanne
11:40	2254	Introducing the new concept of “ocular vasculitis” ABU EL ASRAR AM–Riyadh
12:00	2255	Immunopathology of intraocular inflammation and evolving concepts in immunotherapy DICK AD–Bristol
12:20	2256	How OCT is changing our appraisal of inflammatory retinal diseases DE SMET MD, VAN VELTHOVEN MEJ, VERBRAAK FD–Amsterdam

Fenix III	<b>Free papers : Neuro-ophthalmology</b>	11:00 – 12:30
FP	Pinar AYDIN, Patricia McGETTRICK	

11:00	2261	Binocular vision changes in young adults during a period of 3 years JORGE J, FERNANDES P, ALMEIDA J B, PARAFITA M A–Braga, Santiago Compostela
11:12	2262	Distance Stereoacuity in Intermittent Exotropia HOLMES JM–Rochester, MN
11:24	2263	Thomsen myotonia congenita and strabismus, saccades recording in myotonic diseases SPIRE M, HABAULT C, TILIKETE C, VIAL JC, GRANGE JD–Lyon
11:36	2264	Eyelid and eye movements in Bell's palsy VAN DER WERF F, SMIT A, METSELAAR M–Rotterdam
11:48	2265	A case of cerebral achromatopsia OEHRENS AM, BOSCHI A, DUPREZ T, IVANOIU A–Leuven, Brussels
12:00	2266	Venous retinal vessel response of migraine patients to luminant chromatic and monochromatic flicker application LANZL IM, WIESCHER A, VILSER W, KOTLIAR KE–Munich, Ilmenau
12:12	2267	Two year's training of homonymous hemianopia with flicker stimulation <i>rf</i> RANINEN AN, HENRIKSSON L, VANNI S, HYVÄRINEN LVM, NÄSÄNEN R–Helsinki, Espoo

Gemini I **Functional imaging of the retina** 14:00 – 15:30  
 SIS Rui BERNARDES



14:00	2311	Stiles-Crawford effect BERENDSCHOT TTJM–Maastricht
14:15	2312	Retinal imaging with Multiplanar OCT ROSEN R–New York
14:30	2313	Optophysiology: Non-invasive, depth resolved optical probing of retinal physiology DREXLER W, BIZHEVA K, PFLUG R, POVAZAY B, HERMANN B, SATTMANN H, QUI P, ANGER E.M., REITSAMER H, POPOV S, TAYLOR JR, AHNELT PK–Vienna
14:45	2314	Hyperspectral imaging of the retina: principles and applications NASCIMENTO SMC–Braga
15:00	2315	Functional and morphological retinal data fusion BERNARDES R–Coimbra
15:15	2316	Discussion BERNARDES R–Coimbra

Gemini III **Corneal nerves and dry eyes** 14:00 – 15:30  
 SIS Linda MÜLLER



14:00	2321	Dry eye related changes in the anterior eye segment DARTT DA–Boston, MA
14:18	2322	In vivo confocal microscopy of dry eye patients with SS and non-SS BENITEZ DE CASTILLO JM–Madrid
14:36	2323	Ultrastructural changes of the corneal nerves after LASIK MÜLLER LJ–Amsterdam
14:54	2324	Is there a difference in corneal nerves in dry eye patients and patients after refractive surgery? TUISKU IS, TERVO TM–Helsinki
15:12	2325	Possible approaches to treat patients with dry eyes KRUSE F–Erlangen

Pegasus **Free papers : Physiology / Biochemistry / Pharmacology 3** 14:00 – 15:30  
 FP Irina OBROSOVA, Alain BRON

14:00	2331	VEGF concentration in vitreous from diabetic patients is not associated with hmg-coa reductase inhibitor (statin) therapy LIINAMAA MJ, SAVOLAINEN MJ–Oulu
14:12	2332	Antioxidant and angiogenic protein expression in diabetic retinopathy DE SOUZA RAMALHO P, PEREIRA DA SILVA A, THIRAN C, FONTES G, BICHO MP–Lisbon
14:24	2333	Can erythropoietin protect retinal cell injury in diabetic retinopathy ? DE SOUZA RAMALHO P, PEREIRA SILVA A, THIRAN C, BICHO M–Lisbon
14:36	2334	Docosahexaenoic acid and ether-lipid changes and ERG alterations during retinal ischemia-reperfusion in the rat BRON AM, ACAR N, JOFFRE C, GREGOIRE S, ARNAVIELLE S, GARCHER C, BRETILLON L–Dijon
14:48	2335	Early Diabetes-Induced Changes in the Retina: Comparison of Rat and Mouse OBROSOVA IG, PACHER P, SEIGEL G, STEVENS MJ–Baton Rouge, LA, Rockville, MD, Buffalo, NY, Ann Arbor, MI
15:00	2336	Expression of EphrinB2 and EphB4 in a mouse model of oxygen-induced retinopathy (OIR) EHLKEN C, MARTIN G, HANSEN LL, AGOSTINI HT–Freiburg

**Ophthalmic Research  
Lecture**

15:45 – 16:30  
 Fenix III

**The Spark of Life? A Fundamental Role for Electric Fields in Guiding Cell Behaviour**

John FORRESTER—Aberdeen  
 Introduction by Andrew DICK



Vega	<b>FRO 2</b>	14:00 – 15:30
Joint M.	Marie - José TASSIGNON	

14:00	2341	Inhibition of intra-ocular inflammation mediated by adeno-associated virus gene transfer of SOCS1 and IκBm DE GREEF S
14:20	2342	Delivery of therapeutic nucleic acids in RPE cells by PEG-Lipoplex PEETERS L
14:40	2343	Effect of nucleotides on TNF and IFN gamma signaling in human retinal epithelial cells BOUFFIOUX C
15:00	2344	Study of the expression of aquaporins in diabetic retinopathy LIENART M

Fenix I	<b>Immunomodulatory therapy in ocular inflammatory diseases</b>	14:00 – 15:30
SIS	Andrew David DICK	

14:00	2351	Immunomodulation of TH1 response a science overview...what are we trying to achieve? DICK AD–Bristol
14:18	2352	TNF blockade in ocular inflammatory disease SMITH J–Portland, OR
14:36	2353	Alpha Interferon therapy in Behcet's disease DEUTER C–Tuebingen
14:54	2354	Overview of alternative pathways for biologic therapy DE SMET M–Amsterdam
15:12	2355	Gene therapy for ocular inflammatory disease ALI R–London

Fenix III	<b>Free papers : Anatomy/Cell Biology 1 - Posterior Segment</b>	14:00 – 15:30
FP	Hannu UUSITALO	

14:00	2361	Induction of RPE Differentiation Markers in Human Mesenchymal Stem Cells from Adipose Tissue VOSSMERBAEUMER U, KUEHL S, KERN S, KLÜTER H, EICHLER H, JONAS JB, BIEBACK K–Mannheim
14:12	2362	Induction of alphaB-Crystallin in optic nerve head astrocytes by TGF-beta and hypoxia YU AL, BURGER J, LÜTJEN-DRECOLL E, KAMPIK A, WELGE-LUSSEN UC–Munich, Erlangen
14:24	2363	Human retinal microglia direct retinal progenitor cell proliferation and differentiation BALASUBRAMANIAM B, DICK A D, CARTER D A, MAYER E–Bristol
14:36	2364	Comparison of the in vitro expression profile of primary retinal ganglion cells and retinal cell lines, RGC-5 and R28 DAVIES VJ, VOTRUBA M–Cardiff
14:48	2365 <i>rf</i>	Expression of endostatin in human choroidal neovascular membranes secondary to age related macular degeneration TATAR O, ADAM A, ROHRBACH J MARTIN, LUCKE K, SHINODA K, BARTZ-SCHMIDT KU, GRISANTI S–Tuebingen, Bremen, Tokyo
14:54	2366 <i>rf</i>	Ultrastructural analysis of photoreceptor neurogenesis in the adult monkey and human far peripheral retina CUENCA N, MARTÍNEZ-NAVARRETE G, MARTÍN-NIETO J, ANGULO A–Alicante
15:00	2367 <i>rf</i>	Alpha-Synuclein-containing synaptic ribbons, outer segment disks and desmosome-like junctions in the primate retina. MARTINEZ-NAVARRETE G, ANGULO A, HERRERO MT, MARTÍN-NIETO J, CUENCA N–Alicante, Murcia

## Poster session

16:30 – 17:30  
Neptuno**Cornea / Ocular Surface, Anatomy / Cell Biology, Neuro-ophthalmology / Strabismology, Physiology / Biochemistry / Pharmacology**

Jean-Jacques GICQUEL, Luc MISSOTTEN, Lene MARTIN, Johan PRZYDRYGA

Gemini I	<b>Emerging AMD therapies and novel administration techniques</b>	17:30 – 19:00
SIS	Jose CUNHA-VAZ	



17:30	2411	<b>Chairman's introduction</b> CUNHA-VAZ J–Coimbra
17:45	2412	<b>Early detection and prevention of wet AMD</b> SILVA R, FARIA DE ABREU JR, CUNHA VAZ JG–Coimbra
18:00	2413	<b>Pathophysiology of AMD - evolving concepts, new therapeutic targets</b> DE SMET MD–Amsterdam
18:15	2414	<b>Overview of clinical results with new therapies</b> KOROBELNIK JF–Bordeaux
18:30	2415	<b>Drug delivery and novel administration procedures</b> LEYS A, ANECORTAVE ACETATE STUDY GROUPS–Leuven
18:45		<i>Discussion</i>

Gemini III	<b>Free papers : Cornea 1 - Keratoconus and corneal transplantation</b>	17:30 – 19:00
FP	Paul Louis DIGHIERO, Bernard D. DUCHESNE	

17:30	2421	<b>Cytokine-mediated Regulation of Extracellular Superoxide Dismutase in Normal and Diseased Human Keratocytes</b> BEHNDIG AB, ÅSTRÖM E, MARKLUND SL–Umeå
17:42	2422	<b>Corneal thinning in keratoconus</b> MEEK KM, BOOTE C, HAYES S, TUFT S, BRON AJ–Cardiff, London, Oxford
17:54	2423	<b>Protection of endothelial cell death against oxidative stress during acute corneal graft rejection</b> BOURGES J-L, VALAMANESH F, RENARD G, DEKOZAK Y, BENEZRA D, BEHAR–COHEN F–Paris, Jerusalem
18:06	2424 <i>rf</i>	<b>Modified Microkeratome-Assisted Posterior Lamellar Keratoplasty Using A Tissue Adhesive</b> BEHRENS A, PIROUZMANESH A, HERRETES S, REYES JMG, SUWAN-APICHON O, CHUCK RS, WANG DA, ELISSEEFF JH, STARK WJ–Baltimore
18:12	2425 <i>rf</i>	<b>Keratocyte apoptosis in keratoconus: A function of TIMP-3 and TIMP-1 synthesis?</b> SMITH VA, MATTHEWS FJ–Bristol
18:18	2426 <i>rf</i>	<b>Agreement between two non-contact specular microscopes: TOPCON SP2000 versus RHINETEC</b> THURET G, NGUYEN F, ZHAO M, DEB N, GAVET Y, GAIN P–Saint-Etienne
18:24	2427 <i>rf</i>	<b>Osteo-odonto Keratoprosthesis: A 40-Year Review</b> MICHAEL R, SRIPATTANAWAT R, ALVAREZ A, TEMPRANO J, DE LA PAZ MF, CHAROENROOK V, ALVAREZ DE TOLEDO J, BARRAQUER RI–Barcelona
18:30	2428 <i>rf</i>	<b>The assessment of corneal endothelium before and after cornea storage in tissue culture conditions</b> JIRSOVA K, TOMSU S, ANDRLE J, FILIPEC M–Prague
18:36	2429 <i>rf</i>	<b>The presence of HLA-DR positive cells in human corneas stored under hypothermic or tissue culture conditions</b> AL FAKIH A, JIRSOVA K, FILIPEC M–Prague

Pegasus	<b>Neuro-ophthalmic emergencies</b>	17:30 – 19:00
SIS	Aki KAWASAKI, François-Xavier BORRUAT	

17:30	2431	<b>Unusual presentations of giant cell arteritis</b> BOSCHI A–Brussels
17:45	2432	<b>Mucormycosis: manifestations, diagnosis and treatment</b> BORRUAT FX–Lausanne
18:00	2433	<b>Toxic and Metabolic Neuro-Ophthalmic Emergencies</b> MILEA D–Paris
18:15	2434	<b>Acute Third Nerve Palsy: who needs an arteriogram?</b> KAWASAKI A–Lausanne
18:30	2435	<b>Painful Horner's Syndrome</b> KAWASAKI A–Lausanne
18:45		<i>Discussion</i>

Vega	<b>Novel Ophthalmic Technologies III</b>	17:30 – 19:00
SIS	Tom MISSOTTEN	

**IMAGING THE CORNEA**

17:30	2441	Multiphoton microscopy KOENIG K, RIEMANN I, HUSS C, KRAUSE M, BAGOUI W, LEHARZIC R–St. Ingbert, Homburg, Jena
17:45	2442	Wide field White Light OCT BOCCARA AC–Paris

**PRESBYOPIA: NEW PATHWAYS FOR A CURE**

18:00	2443	Multi-piece accommodating IOLs HO A–Sydney
18:15	2444	fs-laser induced elasticity changes to improve presbyopic lens accommodation LUBATSCHOWSKI H–Hannover

**IMAGING THE RETINA**

18:30	2445	Fourier domain OCT : high resolution 3D imaging WOJTKOWSKI M, KOWALCZYK A–Torun
18:45	2446	Adaptic optics for imaging the retina FERNANDEZ EJ–Vienna

Fenix I	<b>Paediatric Uveitis : progress in its appraisal and management</b>	17:30 – 19:10
SIS	Bahram BODAGHI, Carl P HERBORT	

17:30	2451	Introduction BODAGHI B–Paris
17:35	2452	Epidemiology of paediatric uveitis TUGAL-TUTKUN I–Istanbul
17:50	2453	Diagnosis and investigation of paediatric uveitis DAVIES J
18:05	2454	Paediatric Behçet's uveitis TUGAL-TUTKUN I–Istanbul
18:20	2455	Current knowledge on uveitis related to juvenile idiopathic arthritis PLEYER U, KEITZER R–Berlin
18:35	2456	Medical Management of paediatric uveitis HERBORT CP, BOUCHENAKI N–Lausanne
18:50	2457	Surgical Management of paediatric Uveitis BODAGHI B–Paris
19:05		<i>Discussion</i>

Fenix III	<b>Free papers : Anatomy/Cell Biology 2 - Anterior Segment &amp; Adnexa</b>	17:30 – 19:00
FP	Erich KNOP, Frans VAN DER WERF	

17:30	2461	Morphologic and volumetric studies of the human Meibomian glands BRON AJ, KOZAK I, KLUCHOVA D, KUCHAROVA K, MARSALA M, TIIFANY JM–Oxford, La Jolla, CA, Kosice
17:42	2462	Ultrastructural anatomy of M-cells, germinal centers and high endothelial venules in CALT follicles of the rabbit KNOP E, KNOP N–Berlin, Hannover
17:54	2463	Human corneal epithelial cell migration and expression of laminin-5 by insulin-like growth factor-1(IGF-1) in cultured human corneal epithelial cell LEE HK, KIM EK, LEE JH, HAN SH–Seoul
18:06	2464	Identification of c-Kit expressing cells in the Ciliary Muscle of Cebus apella VERONESE RODRIGUES ML, PAULA JS, SOUZA ESMV, SOUZA NV, GARCIA SB–Ribeirão Preto
18:18	2465	Myofibrillar ultrastructure of the human extraocular muscles CARLSSON E, PEDROSA DOMELLÖF F–Umeå
18:30	2466 <i>rf</i>	Mediation of Ghrelin's relaxing effect on iris sphincter and dilator muscles ROCHA DE SOUSA A, SARAIVA J, FARIA PA, FALCÃO REIS F, LEITE-MOREIRA A–Porto
18:36	2467 <i>rf</i>	The $\beta$ -defensin HBD2 induces specific patterns of Ca <sup>2+</sup> responses in conjunctiva cells (IOBA-NHC) associated with activation of L-type channels MERGLER SM, SCHLORF TS, RECKER KR, PLEYER UP, DIEBOLD YD, PAULSEN FP–Berlin, Halle, Valladolid

**CORNEA / OCULAR SURFACE**

201 An experimental model to measure real intraocular pressure (IOP) in LASIK  
HERNANDEZ VERDEJO JL, BOLIVAR G, ROMAN JM, TORRES J, TEUS MA—Madrid

202 Ocular and Dermal Hydration: The Release of Natural Moisturising Agents from Hydrogels  
TIGHE B, BAHIA R—Birmingham

203 Femtosecond Laser Energy Thresholds for Surgical Use in Corneal Tissue  
VOSSMERBAEUMER U, JONAS JB—Mannheim, Heidelberg

204 Effectiveness & safety of Astigmatic Keratotomy for general ophthalmologist  
ARIF FA, MORIARTY AP—Stockport

205 Mycophenolic Acid Modifies Fibrotic Responses by Human Tenon Fibroblasts in Vitro  
AMER RA, PUXEDDU IP, ANTEBY IA, LEVI-SCHAFFER FL-S, SOLOMON AS—Jerusalem

206 Proliferative capacity and cytokeratin expression in the aberrant endothelium of posterior polymorphous corneal dystrophy  
MERJAVÁ S, JIRSOVA K, VESELA V, MARTINCOVA R, LISKOVA P, FILIPEC M—Prague

207 The depletion of macrophages and/or CD4+ cells prolongs corneal xenograft survival  
VITOVA A, PINDJAKOVA J, FILIPEC M, JIRSOVA K, ZAJICOVA A, HOLAN V—Prague

208 Flurbiprofen decreases the gene expression of TNF- in rabbit corneas exposed to artificial sunlight in vivo  
KARAMPATAKIS VE, BASLI E, GOULAS A, VARSAMIDIS K, KOMNENOU A, KAROUTIS A, KOKKAS B, MIRTOSU-FIDANI V—Thessaloniki

209 Advantages of Dacrio TC versus Traditional Dacriocistography  
PESCE G, MESIANI MAZZACUVA F, CATALANO C, CARNOVALE SCALZO G, SCORCIA V, BRUZZICHESSI D, PARDATKSCHEK R, SCORCIA G—Catanzaro

210 Within and Between Session Repeatability of Topographic Data Using Medmont E-300 Corneal Topographer  
FERNANDES P, GONZÁLEZ-MÉIJOME JM, QUEIRÓS A, JORGE J, DIAZ-REY A, ALMEIDA JB—Braga

211 Traumatic wound dehiscence after penetrating keratoplasty  
WILLIAMS MA, GAWLEY SD, FRAZER DG—Belfast

212 Validity of Nelson's Classification in the long term follow-up of ocular burns  
GICQUEL JJ, BALAYRE S, MILINCHEVITCH S, MERCIÉ M, DIGHIÉRO PL—Poitiers

213 Morphological changes in optic nerve head evaluated with oct before and after LASIK surgery  
ARRANZ E, ROMÁN JM, SÁNCHEZ JM, MARINA C, TEUS MA—Madrid

214 The role of Hyaluronic acid in ocular and joint lubrication  
RASUL N, TIGHE B—Birmingham

215 The effect of wearing time in refractive index of conventional and silicone hydrogel contact lenses: a comparative study  
LIRA M, OLIVEIRA M, VILAR E—Braga, Santiago de Compostela

216 Pre-lens tear film stability before and after contact lenses wear  
LIRA M, OLIVEIRA ME, VILAR EY-P, SANTOS L, AZEREDO J—Braga, Santiago de Compostela

217 Effects of biglycan on keratocytes proliferation  
KOULIKOVSKA M, PODSKOCHY A, FAGERHOLM P—Linköping

218 Refractive Index and Water Content of Conventional and Silicone Hydrogel Contact Lenses  
GONZALEZ-MEIJOME JM, LOPEZ-ALEMANY A, LIRA M, ALMEIDA JB, PARAFITA MA—Braga, Valencia, Santiago de Compostela

219 Evaluation of Brix Scales to Correlate Refractive Index and Water Content of Current Conventional and Silicone Hydrogel Contact Lenses  
GONZALEZ-MEIJOME JM, LOPEZ-ALEMANY A, LIRA M, ALMEIDA JB, PARAFITA MA—Braga-Valencia, Braga, Santiago de Compostela

220 Silicone-hydrogel contact lenses – microbial colonisation and hydrophobicity  
SANTOS L, LIRA M, REAL OLIVEIRA MECD, OLIVEIRA R, AZEREDO J—Braga

221 Protein adsorption to silicone-hydrogel contact lenses – An in vivo study  
SANTOS L, LIRA M, REAL OLIVEIRA MECD, OLIVEIRA R, AZEREDO J—Braga

222 PRK and LASEK in pediatric patients with high myopic anisometropia and amblyopia  
AUTRATA R, REHUREK J, VODIČKOVÁ K, PYROCHTOVÁ S—Brno

223 Phototherapeutic keratectomy in children with a long term follow up  
AUTRATA R, REHUREK J, VODIČKOVÁ K, PYROCHTOVÁ S, HELMANOVÁ I—Brno

224 Inflow of Ocular Surface Fluid into the Anterior Chamber in Patients after Phacoemulsification through Sutureless Corneal Cataract Wounds  
BEHRENS A, STARK WJ, HERRETES S, PIROUZMANESH A, REYES JMG, MCDONNELL PJ—Baltimore

225 Modified Microkeratome-Assisted Posterior Lamellar Keratoplasty Using A Tissue Adhesive  
*rf*  
BEHRENS A, PIROUZMANESH A, HERRETES S, REYES JMG, SUWAN-APICHON O, CHUCK RS, WANG DA, ELISSEFF JH, STARK WJ—Baltimore

226 Keratocyte apoptosis in keratoconus: A function of TIMP-3 and TIMP-1 synthesis?  
*rf*  
SMITH VA, MATTHEWS FJ—Bristol

227 Agreement between two non-contact specular microscopes: TOPCON SP2000 versus RHINETEC  
*rf*  
THURET G, NGUYEN F, ZHAO M, DEB N, GAVET Y, GAIN P—Saint-Etienne

228 Osteo-odonto Keratoprosthesis: A 40-Year Review  
*rf*  
MICHAEL R, SRIPATTANAWAT R, ALVAREZ A, TEMPRANO J, DE LA PAZ MF, CHAROENROOK V, ALVAREZ DE TOLEDO J, BARRAQUER RI—Barcelona

229 The assessment of corneal endothelium before and after cornea storage in tissue culture conditions  
*rf*  
JIRSOVA K, TOMSU S, ANDRLE J, FILIPEC M—Prague

230 The presence of HLA-DR positive cells in human corneas stored under hypothermic or tissue culture conditions  
*rf*  
AL FAKIH A, JIRSOVA K, FILIPEC M—Prague

231 Presence of IgE Antibody and Kinin Components in Atopic and Non-Atopic Contact Lens Wearing Patients  
*rf*  
MANN AM, TIGHE BJ—Birmingham

232 Expression Of Focal Adhesion Protein PINCH In Alkali Injured Corneas And Role Of PMNs  
*rf*  
BOURGHARDT PEEBO B, GAN L, FAGERHOLM P—Linköping

233 Corneal wound healing after intrastromal femtosecond laser keratectomy  
*rf*  
MELTENDORF C, BURBACH GJ, BÜHREN J, OHRLOFF C, DELLER T—Frankfurt am Main

234 NGF treatment and corneal wound healing  
*rf*  
BLANCO-MEZQUITA JT, MERAYO-LLOVES J, MARTÍNEZ-GARCÍA C, MAR-SARDAÑA S, MARTÍNEZ-OSORIO H, TORRES R, GONZÁLEZ-PARRA M, BONINI S, LAMBIASE A—Valladolid, Rome

235 The Nature and Fate of Tear Lipids in Contact Lens Wear  
*rf*  
MANN A, CAMPBELL D, GRIFFITH G, TIGHE B—Birmingham

236 Visual recovery following PRK using corneal epithelium brushing and alcoholic dehydration : a confocal microscopy study  
*rf*  
PICCIRILLO V, DI NUZZO A, RAO V—Maddaloni

237 Influence of multipurpose solutions on the protein composition of the tear film  
*rf*  
GRUS FH, BOZKURT N, PFEIFFER N—Mainz

238 Frictional and lubricity changes in contact lenses during wear  
*rf*  
MAHOMED A, NASSO M, TIGHE BJ—Birmingham

239 Novel Ophthalmic Biomaterials  
*rf*  
MAHOMED A, HENLEY C, TIGHE BJ—Birmingham

240 Silicone Hydrogels: Trends in Products and Properties  
*rf*  
FRANKLIN V, ROSS G, NASSO M, LYDON F, TIGHE B—Birmingham

241 Immunomodulatory Role of VIP in a Murine Model of P. aeruginosa-Induced Keratitis  
*rf*  
SZLITER EA, LIGHVANI S, HAZLETT LD—Detroit

242 Corneal toxicity study of Perfluorohexyloctane in rabbit eyes  
*rf*  
DIAFAS SG, LAKE S, KARAMPATAKIS VE, KARDASOPOULOS AV, STANGOS NT, MANTHOS AK—Thessaloniki

243 Corneal Crystallin Expression in Human Repair Phenotype Keratocytes  
*rf*  
MCDERMOTT AM, PEI Y, SHERRY DM—Houston

244 Numerical simulation of corneal transport processes  
*rf*  
TIGHE B, LI LY—Birmingham

245 Cellular activity in human re-grafts 1 – 30 years primary surgery  
*rf*  
GAN L, FAGERHOLM P, STENEVI U—Linköping, Göteborg

246 Evaluation of Megacell MEM as a corneal storage medium  
*rf*  
SMITH VA—Bristol

**ANATOMY / CELL BIOLOGY**

247 Biomechanics of Orbital Apex Fracture Following Trauma to the Malar Eminence  
TRIARIDIS S, KARAMPATAKIS VE, CONSTANTINIDIS J, GIGIS P—Thessaloniki

248 A mouse model for Stickler's Syndrome: Ocular phenotype of mice carrying a targeted heterozygous inactivation of type II (pro)collagen gene (Col2a1)  
KAARNIRANTA K, IHANAMÄKI T, SAHLMAN J, PULKKINEN H, TAMMI R, LAMMI MJ, UUSITALO H, HELMINEN H—Kuopio, Helsinki

249 Localisation of a novel keratan sulphate stub neopeptide monoclonal antibody BKS-1 in normal human cornea, sclera and limbus  
AKHTAR S, KERR, BC, HAYES T, CATERSON B, MEEK KM—Cardiff

250 Evaluation of the In Vitro Biocompatibility of Degradable Biopolymers in Ocular Cell Cultures  
HUHTALA A, SALMINEN L, POHJONEN T, KAARNIRANTA K, UUSITALO H—Tampere, Kuopio

251 Biological response of an oil ferrofluid in the rabbit eye  
VILLAFRUELA I, SARMIENTO B, TEJADA P—Madrid

252 Transforming Growth Factor – $\beta$  in developing primate foetal retina  
ALLENDE A, NATOLI R, PROVVIS J—Sydney, Canberra

253 Intraorbital optic nerve crush-induced retinal ganglion cell death. Degeneration and neuroprotection with BDNF, NT-4 or CNTF  
VIDAL-SANZ M, PARRILLA-REVERTER G, SOBRADO P, CANOVAS I, BERNAL JM, SALINAS M, AGUILERA ME—Murcia

254 Phototoxic retinal degeneration causes retinal ganglion cell death in adult rats  
VILLEGAS PEREZ MP, MARCO-GOMARIZ MA, HURTADO-MONTALBÁN N, BERNAL GARRO JM, VIDAL-SANZ M—Murcia

255 Quantitative analysis of retinal ganglion cells that project to the superior colliculi in adult rats and mice  
VILLEGAS PEREZ MP, SALINAS M, MAYOR S, HOLMES T, LUND RD, BERNAL JM, CANOVAS I, AGUILERA ME, VIDAL-SANZ M—Murcia, Utah

256 Hsp25 and Hsc70 expression in retina of *trkB* transgenic mice and their wild-type controls  
RANTALA JA, KALESNYKAS G, KAARNIRANTA K, CASTREN E, UUSITALO H—Kuopio, Helsinki

257 Behaviour of glia in a model of chronic ocular hypertension  
RAMIREZ AI, SALAZAR JJ, DE HOZ R, ROJAS B, TRIVIÑO A, VILLEGAS-PEREZ MP, MAYOR-TORREGLOSA S, SALINAS M, VIDAL-SANZ M, RAMIREZ JM—Madrid, Murcia

258 Effect of nucleotides on the activation of RPE cells by pro-inflammatory cytokines  
BOUFFIQUX C, JUDICE DE MENEZES L, SUAREZ-GONZALES N, CASPERS L, BRUYNS C, BOEYNAEMS JM, WILLERMAIN F—Brussels

259 TGF- $\beta$  protects RPE via an increase of Ser-59 phosphorylated alphaB-crystallin  
YU AL, ALGE CS, KAMPIK A, BLOEMENDAL H, WELGE-LUSSEN UC—Munich, Nijmegen

260 Failure of Limited Proteolysis of Pigment Epithelium-Derived Factor (PDEF) in Tenon's Capsule of Patients with Progressive Myopia  
LAZUK AV, IOMDINA EN, KOSTANYAN IA, ZHOKHOV SS—Moscow

261 Expression of endostatin in human choroidal neovascular membranes secondary to age related macular degeneration  
*rf* TATAR O, ADAM A, ROHRBACH J, MARTIN, LUCKE K, SHINODA K, BARTZ-SCHMIDT KU, GRISANTI S—Tuebingen, Bremen, Tokyo

262 Ultrastructural analysis of photoreceptor neurogenesis in the adult monkey and human far peripheral retina  
*rf* CUENCA N, MARTÍNEZ-NAVARRETE G, MARTÍN-NIETO J, ANGULO A—Alicante

263 Alpha-Synuclein-containing synaptic ribbons, outer segment disks and desmosome-like junctions in the primate retina  
*rf* MARTÍNEZ-NAVARRETE G, ANGULO A, HERRERO MT, MARTÍN-NIETO J, CUENCA N—Alicante, Murcia

264 Mediation of Ghrelin's relaxing effect on iris sphincter and dilator muscles  
*rf* ROCHA DE SOUSA A, SARAIVA J, FARIA PA, FALCÃO REIS F, LEITE-MOREIRA A—Porto

265 The  $\beta$ -defensin HBD2 induces specific patterns of Ca<sup>2+</sup> responses in conjunctiva cells (IOBA-NHC) associated with activation of L-type channels  
*rf* MERGLER SM, SCHLORF TS, RECKER KR, PLEYER UP, DIEBOLD YD, PAULSEN FP—Berlin, Halle, Valladolid

## NEURO-OPHTHALMOLOGY / STRABISMOLOGY

266 The role of histology in the diagnosis of a slipped extraocular muscle  
VOROS GV, RESSINIOTIS T, STRONG NP—Newcastle upon Tyne

267 Effectiveness of enhanced medial rectus recession with looped sutures  
RESSINIOTIS T, VOROS GM, KNOWLES E, TIFFIN PAC, ALLCHIN RW—Sunderland, Newcastle upon Tyne

268 Variation of distance and near lateral phorias along the morning  
SOBRADO-CALVO P, VIDAL-LOPEZ J—Murcia

269 Changes in fusional vergences in High School students along the morning  
VIDAL LÓPEZ J, SOBRADO CALVO P—Murcia

270 Comparison of the measurements of lateral phorias with the Bioptr Vision Test and the von Graefe method  
SOBRADO-CALVO P, VIDAL-LOPEZ J—Murcia

271 Effects of orthoptic treatment on the CA/C and AC/A ratios  
BRAUTASET R, JENNINGS A—Stockholm, Manchester

272 The effect of maintenance therapy on amblyopia recurrence following successful primary treatment  
SJÖSTRAND JB, NILSSON J, BAUMANN M—Göteborg

273 Peculiarities of pupillogrammes in healthy persons  
BOYCHUK IRYNA M., BUSHUYEVA NATALIYA N, SLOBODYANIK SVETLANA B, M.H.DUHAIR SHAKER—Odessa

274 Evaluation of optic disc edema using OCT and HRT  
KAMPMPETER BA, JONAS JB—Mannheim

275 Sleep apnea, the most frequent disorder associated with Nonarteritic Anterior Ischemic Optic Neuropathy  
RENARD ER, PALOMBI KP, PEPIN JLP, LEVY PL, DECHAUD CD, CHIQUET CC, MOUILLON MM, ROMANET JPR—Grenoble

276 A flawless MRI can leave you with a headache - Is B-Scan Ultrasonography superior to CT and MRI?  
NESTEL AR, WHITTAKER KW, GIBSON RA—Barnstaple

277 Two year's training of homonymous hemianopia with flicker stimulation  
*rf* RANINEN AN, HENRIKSSON L, VANNI S, HYVÄRINEN LVM, NÄSÄNEN R—Helsinki, Espoo

## PHYSIOLOGY / BIOCHEMISTRY / PHARMACOLOGY

278 Reducing vascularity in complex anterior segment surgery with topical apraclonidine 1%  
SII F, LOCKWOOD A, SHAH P, TODD B—Birmingham

279 A new biodegradable polymer for triamcinolone delivery  
EPERON S, FELT-BAEYENS O, MORA P, LIMAL D, SAGODIRA S, BRETON P, GURNY R, GUEX-CROSIER Y—Lausanne, Geneva, Parma, Paris

280 Expression of MMP's and TIMP by biodegradable biopolymer implants in rat eye  
RÖNNKÖ S, OKSALA E, KAARNIRANTA K, SALMINEN A, TERÄSVIRTA M, UUSITALO H—Kuopio

281 Intravitreal toxicity of Acular and Flurbiprofen  
MUNOZ MORALES A, PEYMAN GA, KIVILCIM M—New Orleans

282 Different Outwardly Rectifying Potassium Currents in the Mouse Retinal R pigment Epithelium  
WIMMERS S, KARL MO, STRAUSS O—Hamburg

283 An animal model to study the relationship between blood pressure and intraocular pressure  
SAVY O, ROMANET JP, NOEL C, MOUILLON M, BOURDON L—Grenoble

284 Endocannabinoid and palmitoylethanolamide levels in eyes with diabetic retinopathy or macular degeneration  
MATIAS I, WANG J, SCHIANO MORIELLO A, NIEVES A, VALENTI M, DI MARZO V, WOODWARD D—Pozzuoli, Irvine

285 In vivo intra-ocular delivery of oligonucleotides using photosensitive vesosomes  
VALAMANESH F, NORMAND N, BEJIANI RA, BENEZRA D, COURTOIS Y, BEHAR-COHEN F—Paris, Jerusalem

286 Curcumin treatment protects rat retinal neurons against excitotoxicity: effect on N-methyl-D-aspartate -induced intracellular Ca<sup>2+</sup> increase  
CARNOVALE SCALZO G, MATTEUCCI A, FRANK C, DOMENICI MR, PARADISI S, SCORCIA V, BRUZZICHESSI D, BALDUZZI M, MALCHIODI-ALBEDI F, SCORCIA G—Catanzaro, Rome

287 How much doxycycline reaches the ocular surface in patients undergoing therapy for ocular surface disease?  
KHAN-LIM D, SMITH VA—Southampton, Bristol

288 Effects of Cyclooxygenase inhibitors on apoptotic retinal ganglion cells  
BRUST A-K, ULBRICH H, PFEIFFER N, GRUS F—Mainz

289 Effects on the ciliary processes after experimental vitreous replacement with Perfluorohexyloctane  
LAKE S, DIAFAS SG, KARAMPATAKIS VE, KOMNENOU AT, NTAMPOS KS, MANTHOS AK—Thessaloniki

290 Cessation of Systane® Lubricant Eye Drops and Return of Signs and Symptoms of Dry Eye  
PRZYDRYGA J, COHEN S, CHRISTENSEN M—Fort Worth, TX, Scottsdale, AZ

291 The effect of smoking on foveal function  
NILSSON M, HENRICSSON A, MARTIN L—Stockholm

292 A Pilot Study Comparing Sub-conjunctival Triamcinolone Injection with Topical Steroid in Controlling Post-Cataract Surgery Inflammation  
CHIAM P, CHAN J, PATEL P, KASABY H—Southend

293 Effects of physical exercise on intraocular pressure after the instillation of brimonidine tartrate eye drops  
KARAMPATAKIS VE, NATSIS K, DIAFAS SG, CHATZIBALIS T, NTAMPOS KS, LAKE S—Thessaloniki

294 Intercellular communication in retinal endothelial is downregulated in response to high glucose by a proteasome dependent mechanism  
*rf* PEREIRA P, GIRÃO H, FERNANDES R—Coimbra



*ever 2005*

**Friday 7 October**



Gemini I **Free papers : Molecular Biology / Genetics / Epidemiology 2** 08:30 – 10:00  
 FP Jonathan JACKSON, Ian BAILEY

08:30	3111	Ocular pathology in Turner's syndrome MULAK M, MISIUK-HOJLO M, SZALINSKI M, WIKIERA B–Wrocław
08:42	3112	Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy SANDGREN OJP, KJELLGREN D, SUHR OB–Umeå
08:54	3113	The comparison of different refractive error cut-off points to define myopia SAW SM, GAZZARD G, LUO HD, FOSTER PJ, SHANKAR A, TAN DTH–Singapore
09:06	3114	Refractive error in urban and rural adult Chinese in Beijing JONAS JB, XU L, LI J, CUI T, HU A, FAN G, ZHANG R, YANG H, SUN B–Mannheim, Beijing
09:18	3115 <i>rf</i>	To ascertain the prevalence of poor vision which exists in boys at a prestigious school in a developing country (Trinidad) DWARIKA D, BHOLA RM, SEEMONGAL DASS R, EMAMALIE S–Birmingham, Sheffield, Trinidad
09:24	3116 <i>rf</i>	Ocular complications and evaluation of quality of life in patients after Stevens-Johnson and Lyell syndromes GUEUDRY J, BINAGHI M, SOUBRANE G, ROUJEAU J-C, BRASSEUR G, MURAINÉ M–Rouen, Créteil
09:30	3117 <i>rf</i>	Missed metal Foreign Bodies SKINNER KC, CHRONI FC, MERRICK CD, GREGORY PTS–St-Leonards-on-Sea
09:36	3118 <i>rf</i>	OPHTEC Iris Reconstruction Lens in Ocular Trauma KULJACA Z, IGNIJATOVIC ZI, DZAKOVIC N, PAVLOVIC S–Belgrade, Giessen

Gemini III **Posterior capsular opacification** 08:30 – 10:00  
 SIS Albert GALAND, Rafael I. BARRAQUER

08:30	3121	After-Cataract Dilemmas VRENSEN G–Leiden
08:45	3122	Clinical aspects of Posterior Capsular Opacification TETZ M–Berlin
09:00	3123	Are the lens epithelial cells the capsular bag's enemy or ally? TASSIGNON MJ–Antwerp
09:15	3124	Surgical options for PCO prevention BARRAQUER RI–Barcelona
09:30	3125	Intra- & post-operative abrasion of the lens epithelial cells by the IOL GALAND A–Liège
09:45	3126	A human capsular bag model for PCO evaluation after IOL implantation - prognostic power? LIEKFELD A–Berlin

Pegasus **Intravitreal use of steroids** 08:30 – 10:00  
 SIS Murat KARACORLU, Jost B JONAS



08:30	3131	Basic mechanisms of steroids (triamcinolone acetonide) JOUSSEN ANTONIA M–Cologne
08:45	3132	Randomized trial on the dosage dependency of low dosage and high dosage of intravitreal triamcinolone JONAS J, SPANAU UH–Mannheim
09:00	3133	Intravitreal steroids associated with laser therapy in the treatment of retinal vascular diseases BANDELLO FB–Udine
09:15	3134	Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy and other diseases KARACORLU M–Istanbul
09:30	3135	Duration of the effect of intravitreal triamcinolone acetonide JONAS J, SPANAU UH, DEGENERING RF, KREISSIG I, AKKOYUN I–Mannheim
09:45	3136	New techniques for delivery of steroids KUPPERMAN L

Vega **OOG 1 Pathology/Oncology** 08:30 – 10:00  
 Joint M. Laurence DESJARDINS, Edoardo MIDENA

08:30	3141	Choroidectomy versus choroidectomy associated with brachytherapy PRIMAVERA V, IACULLI C, ERCOLE I, DELLE NOCI N–Foggia
08:45	3142	Associated transpupillary thermotherapy and proton beam for posterior choroidal melanoma DESJARDINS L, DENDALE R, LUMBROSO L, LEVY C, DELACROIS S, NAURAYE C, PLANCHER C, ASSELAIN B–Paris, Orsay
09:00	3143	Comparison between Ruthenium-106 brachytherapy and sandwich therapy of Ruthenium-106 brachytherapy with Transpupillary Thermo Therapy (TTT) in 161 patients LY LV–Leiden
09:15	3144	Iodine 125 Episcleral Brachytherapy for Circumscribed Choroidal Hemangioma SAORNIL ALVAREZ MA, BIANCIOTTO C, BLANCO G, MUIÑOS Y, ALMARAZ A, DE FRUTOS JM, GIRALDO A, LOPEZ-LARA F–Valladolid
09:30	3145	Long-term survival in choroidal melanoma after 60Co brachytherapy ROMANOWSKA DIXON B, SZUSCIC I–Krakow
09:40	3146	Dose, dose rate and secondary effects in episcleral brachytherapy DE FRUTO BARAJA JM, SAORNIL MA, HINCAPIE J, MUIÑOS Y, ALMARAZ A, LOPEZ-LARA F, GIRALDO A–Valladolid
09:50	3147	Survival of largest uveal melanomas after primary enucleation GAMBRELLE J, KODJIKIAN L, GRANGE JD–Lyon

Fenix I **Free papers : Cornea 2 - Inflammation / Dry Eye** 08:30 – 10:00  
 FP Philippe KESTELYN, Jose BENITEZ-DEL-CASTILLO

08:30	3151	Towards a standardised technique for meibometry TIFFANY JM, LAVRIC A, YOKOI N–Oxford, Ljubljana, Kyoto
08:42	3152	A Comparison of Systane® Lubricant Eye Drops versus Refresh Tears Lubricant Eye Drops when used as Supportive Therapy with Cyclosporine (0.05%) Ophthalmic Emulsion PRZYDRYGA J, SALL K, COHEN S, CHRISTENSEN M–Fort Worth, TX, Bellflower, CA, Scottsdale, AZ
08:54	3153	Efficacy of an HP-Guar based lubricant eye drop in the treatment of dry eye disease MESSMER EM, GASS CA–Munich
09:06	3154	Corneal sensitivity and nerve morphology in primary Sjögren's syndrome TUISKU IS, KONTTINEN YT, TERVO TM–Helsinki
09:18	3155 <i>rf</i>	Presence of IgE Antibody and Kinin Components in Atopic and Non-Atopic Contact Lens Wearing Patients MANN AM, TIGHE BJ–Birmingham
09:24	3156 <i>rf</i>	Expression Of Focal Adhesion Protein PINCH In Alkali Injured Corneas And Role Of PMNs BOURGHARDT PEEBO B, GAN L, FAGERHOLM P–Linköping

Fenix III **Workshop: Mouse model and phenotypes** 08:30 – 10:00  
 Workshop Jochen GRAW

08:30	3161	Mouse Vision Phenotyping SCHAEFFEL F–Tuebingen
08:48	3162	Corneal curvature in the mouse VOTRUBA M–Cardiff
09:06	3163	OLCI: a new tool to screen for mouse mutants, which are affected in eye growth PUK O, DALKE C, GRAW J–Neuherberg
09:24	3164	Measurement of intraocular pressure in mice REITSAMER HAR–Salzburg
09:42	3165	Screening mice for vision DALKE C, FAVOR J, PUK O, GRAW J–Neuherberg

**Keynote Lecture**

10:15 – 10:55  
 Fenix III

**The Cause and Prevention of Nuclear Cataracts: Oxygen and the Vitreous Body**

David BEEBE — St Louis, Missouri  
 Introduction by Jochen GRAW



Gemini I	<b>Workshop: Epidemiology techniques</b>		11:00 – 12:30
Workshop	Seang Mei SAW		

11:00	3211	Study design in clinical ophthalmology SAW SM–Singapore
11:20	3212	Understanding basic statistics in ophthalmology SAW SM–Singapore
11:40	3213	The design and conduct of randomized controlled trials SAW SM–Singapore
12:00		Discussion

Gemini III	<b>Free papers : Glaucoma 1 - Diagnosis</b>		11:00 – 12:30
FP	Thierry ZEYEN, Alain BRON		

11:00	3221	Optic disc hemorrhages and progression to glaucoma in the European Glaucoma Prevention Study (EGPS) STALMANS I, ZEYEN T, MIGLIOR S, PFEIFFER N, CUNHA-VAZ J, ADAMSONS I, EGPS STUDY GROUP–Leuven, Monza, Mainz, Coimbra, Lafayette Hill
11:12	3222	Early Changes in Sub-retinal Layers of the Macular Region and the Optic Nerve Head in Ocular Hypertensive Non-Human Primates DOELEMAYER A, POLSKA EA, SCHMETTERER L, DREXLER W–Basel, Vienna
11:24	3223	Electroretinographic and retinal lipid modifications in a rat model of glaucoma BRON AM, ACAR N, ARNAVIELLE S, GREGOIRE S, JOFFRE C, BRETILLON L, GARCHER C–Dijon
11:36	3224 <i>rf</i>	Central corneal pachymetry in children with congenital glaucoma after trabeculotomy OBERACHER-VELTEN I, LORENZ B–Regensburg
11:42	3225	Correlation between Ocular Pulse Amplitude and Visual Field Defects VULSTEKE C, ZEYEN T–Antwerp, Leuven
11:54	3226 <i>rf</i>	Retrobulbar hemodynamics in asymmetric glaucoma REMKY A, PLANGE N, KAUP M, AREND O–Aachen
12:00	3227	Measurement of cytokine secretion by multiplex bead analysis in tears of glaucoma patients with preserved topical treatment GARCHER CREUZOT CP, MALVITTE L, LAFONTAINE PO, MONTANGE T, LIZZARD G, BRON AM–Dijon

Pegasus	<b>Physiopathology based treatment of macular oedema</b>		11:00 – 12:30
SIS	Constantin POURNARAS		

11:00	3231	Physiopathology of macular oedema AGOSTINI HT–Freiburg
11:18	3232	Laser treatments for macular oedema related to ischemic microangiopathies DOSSO A–Geneva
11:36	3233	The VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group ADAMIST–New York
11:54	3234	Macular oedema of inflammatory origin: anti-TNF treatments DE SMET M, REMICADE EUROPEAN STUDY IN CHRONIC UVEITIS RESCU–Amsterdam
12:12	3235	Vitreotomy for tractional macular oedema POURNARAS CJ–Geneva

Vega	<b>OOG 2 Pathology/Oncology</b>	11:00 – 12:30
Joint M.	Martine J JAGER, Jacob PE'ER	

11:00	3241	<b>Effect of TSTT on immunological parameters of uveal melanoma</b> JAGER MJ, DENNAOUI J, MAAT W, JOURNÉE- DE KORVER H, DE WOLFF-ROUENDAAL D, SCHALIJ-DELFOOS NE–Leiden
11:15	3242	<b>Evolution of pigmented episcleral deposits after brachytherapy of uveal melanoma</b> TOIVONEN P, KIVELÄ T–Helsinki
11:30	3243	<b>Circulating Malignant Cells in Uveal Melanoma</b> CALLEJO SA, ANTECKA E, BLANCO P, EDELSTEIN C, BURNIER MN–Montreal
11:45	3244	<b>New blood markers for metastatic uveal melanoma – a pilot study</b> PE'ER J, FOLBERG, MAJUMDAR D, KALICKMAN I, BARAK V–Jerusalem, Chicago, IL
12:00	3245	<b>FGFR4 Expression in Choroidal Melanoma</b> MADIGAN MC, CORNISH EE, NATOLI R, PROVIS JM–Sydney, Canberra
12:10	3246	<b>Causes and consequences of exudative retinal detachments after protons for uveal melanomas</b> GRANGE JD, KODJIKIAN L, CHAUVEL P, GAMBRELLE J, ABI AYAD N–Lyon, Nice
12:20	3247	<b>New iris colour classification and its relationship with uveal melanoma</b> MUIÑOS DÍAZ Y, SAORNIL ALVAREZ MA, BLANCO MATEOS G, MENDEZ DÍAZ MC, ALMARAZ A, MOREÑO MUÑOZ MF, HINCAPIE J–Valladolid

Fenix I	<b>Free papers : Cornea 3 - Corneal and Ocular Surface Regeneration</b>	11:00 – 12:30
FP	Harminder S DUA, Ashley BEHRENS	

11:00	3251	<b>UBM and in vivo confocal microscopy (IVCM) in wound healing after amniotic membrane transplantation</b> NUBILE M, LANZINI M, TOTO L, COSTANTINO O, CAPPONI AL, GAVALAS C, MASTROPASQUA L–Chieti-Pescara
11:12	3252	<b>Bves Regulates Corneal Epithelial Monolayer Formation</b> CHANG MS, BADER DM–Nashville, TN
11:24	3253	<b>Pterygium Surgery</b> WOOD TO, WILLIAMS EE, HAMILTON DL, WILLIAMS BL–Germantown, Memphis
11:36	3254	<b>Are rabbit bone marrow–derived cells able to contribute to corneal epithelial repair?</b> GUEUDRY J, LAMACZ M, VANNIER J-P, DUCLOS C, METAYER J, BRASSEUR G, MURAINÉ M–Rouen
11:48	3255	<b>Back to Basics-a simple technique for repair of Descemet's membrane tear</b> HUNTBAUGH JA, RAUF A–Nottingham, Burton-on-Trent
12:00	3256 <i>rf</i>	<b>Corneal wound healing after intrastromal femtosecond laser keratectomy</b> MELTENDORF C, BURBACH GJ, BÜHREN J, OHRLOFF C, DELLER T–Frankfurt am Main
12:06	3257 <i>rf</i>	<b>NGF treatment and corneal wound healing</b> BLANCO-MEZQUITA JT, MERAYO-LLOVES J, MARTÍNEZ-GARCÍA C, MAR-SARDAÑA S, MARTÍNEZ-OSORIO H, TORRES R, GONZÁLEZ-PARRA M, BONINI S, LAMBIASE A–Valladolid, Rome

Fenix III	<b>Implications of oxidative stress in the genesis of cataracts</b>	11:00 – 12:30
SIS	Shambhu D. VARMA, Per SÖDERBERG	

11:00	3261	<b>Oxidative stress from UVR in the lens</b> SÖDERBERG P G, LÖFGREN STEFAN, AYALA M, DONG X, MODY V, KAKAR M, MEYER L–Stockholm, Lincoln, Örebro
11:15	3262	<b>Dietary carotenoids and polyphenols in cataract prevention</b> TREVITHICK JR, SUTTON-TREVITHICK CC, COLLINS MM, DZIALOSZYNSKI TM–London, Ontario, Los Angeles, CA
11:30	3263	<b>Cross-Linking of Oxidatively-Modified Crystallin Fragments in vivo</b> SRIVASTAVA OP
11:45	3264	<b>Extrinsic use of intrinsic antioxidants for prevention of cataracts</b> HEGDE KR, VARMA SD–Baltimore
12:00	3265	<b>Vitamin E in protection against cataract</b> AYALA M, SÖDERBERG PG–Örebro, Stockholm
12:15	3266	<b>Induction of Glyoxalase I Fails to Prevent Methylglyoxal Accumulation in Diabetic Mouse Lenses</b> NAGARAJ R, STANISZEWSKA M–Cleveland

Gemini I	<b>Emotion and cognition in vision. Neural mechanisms involved and related clinical conditions</b>		14:00 – 15:30
SIS	Avinoam SAFRAN		

14:00	3311	Functional magnetic resonance imaging of the cerebral response to visual stimulation in medically unexplained visual loss PLANT GT, WERRING DJ, WESTON L, BULLMORE ET, RON MA—London
14:20	3312	Emotional attributes of the image. Neural mechanisms involved in their processing, and clinical implications SAFRAN AB—Geneva
14:40	3313	Out-of-body experience and autoscapy of neurological origin. A visual illusion of one's own-body LANDIS T—Geneva

Gemini III	<b>Free papers : Glaucoma 2 - Therapy</b>		14:00 – 15:30
FP	Anastasios G.P. KONSTAS, Rafael I. BARRAQUER		

14:00	3321	The role of PITX2 in Primary Congenital Glaucoma IDREES F, FRASER S, RUTLAND P, STOILOV I, SARFARAZI M, SOWDEN J, KHAW P T—London, Sunderland, Farmington, CT
14:12	3322 <i>rf</i>	A new scoring system for giant cell arteritis (GCA) - Can the result of a temporal artery biopsy (TAB) be predicted? NESTEL AR, WHITTAKER KW, GIBSON RA, ENOCH BE—Barnstaple, Devon
14:18	3323 <i>rf</i>	Intraocular Pressure Lowering effect of dorzolamide/timolol fixed combination in non-responder glaucoma patients to prostaglandin analogues/prostamides MARTÍNEZ-GARCÍA A, SÁNCHEZ-SALORIO M—Santiago de Compostela
14:24	3324	A randomised, prospective study comparing 90°, 180° and 360° Selective Laser Trabeculoplasty with Latanoprost 0.005% for the control of intraocular pressure in Ocular Hypertension and Open Angle Glaucoma JONES S, O'BRART DPS—London
14:36	3325	Safe-Trabeculectomy Technique: long-term outcome ZEYENT T, GILLIS A, LAFAUT AS, STALMANS I—Leuven, Antwerp
14:48	3326 <i>rf</i>	Safety and efficacy of the Optonol DS version microtube implanted during deep sclerectomy in POAG patients: preliminary results POURNARAS J-A C, MERMOUD A—Lausanne
14:54	3327	Trabeculectomy with Mitomycin C – do we need to work harder in the African-Caribbean population? SHAH P, SII F, LOCKWOOD A—Birmingham
15:06	3328	The use of fibrin glue to secure donor lamellar scleral transplantation in extensive scleral reconstruction in juvenile idiopathic arthritis associated scleromalacia. LOCKWOOD A, SII F, SHAH P—Birmingham

Pegasus	<b>Ophthalmic blood flow regulation &amp; prostaglandins</b>		14:00 – 15:30
SIS	Ivan O HAEFLIGER, Constantin POURNARAS		

14:00	3331	Methods of Evaluation of Optic Nerve Head Circulation POURNARAS CJ—Geneva
14:15	3332	Origin of optic disc near-infrared reflectance changes induced by light stimulation. RIVA CE, LOGEAN E, FALSINI B—Bologna, Galway, Rome
14:30	3333	Vasoactive Response of Porcine and Rabbit Ciliary Arteries to Unoprostone Isopropyl Ester and Free Acid Dissolved either in DMSO or Ethanol ALLEMANN R—Basel
14:45	3334	Effect of Indomethacin on Optic Nerve Head CO <sub>2</sub> -Induced Dilation PETROPOULOS IK, MUNOZ JL, POURNARAS CJ—Geneva
15:00	3335	Indomethacin Reduces Optic Nerve Oxygen Tension STEFANSSON E, PEDERSEN DB, NORGAARD MH, EYSTEINSSON T, KIILGAARD JF, LA COUR M, BANG K, JENSEN PK—Reykjavik, Copenhagen
15:15	3336	Effect of latanoprost on choroidal blood flow regulation in healthy humans SCHMETTERER L, FUCHSJÄGER-MAYRL G, WEIGERT G, POLSKA E, KARL K—Vienna

**Keynote Lecture**15:45 – 16:30  
Fenix III**Assessment of vision - Monitoring impairments and predicting functional abilities**

Ian BAILEY — Berkeley, California

Introduction by Jonathan JACKSON



Vega	<b>OOG 3 Pathology/Oncology</b>		14:00 – 15:30
Joint M.	Maria Antonia SAORNIL ALVAREZ, Theodora HADJISTILIANOU		
14:00	3341	<b>Clinical features of ring melanoma of the uvea: A retrospective report on twenty-three patients</b> AKGUEL H, ANASTASSIOU G, SCHILLING H, SCHUELER A, BORNFELD N–Essen	
14:15	3342	<b>Prognostic factors of liver metastases from uveal melanoma</b> KODJIKIAN L, RIVOIRE M, GARWEG JG, GRANGE JD–Lyon, Bern	
14:30	3343	<b>Age at diagnosis and bilateralization of unilateral retinoblastoma</b> HADJISTILIANOU T, DE FRANCESCO S, LORE C, MASTRANGELO D, MENICACCI F–Siena	
14:45	3344	<b>Chemoreduction and local treatment for intraocular retinoblastoma</b> ROMANOWSKA DIXON B, KOBYLARZ J, PIWOWARCZYK A, BALWIERZ W, DŁU NIEWSKA A–Krakow	
15:00	3345	<b>Eyelid tumors: clinicopathological correlation of 1334 cases</b> MENDEZ MC, SARASA JL, GARCÍA-SANDOVAL B, BLANCO G, SAORNIL MA, FERNANDEZ N, PIGAZO JM–Valladolid, Madrid	
15:10	3346	<b>Benign mixed tumour of the eyelid</b> DIXON RS, SWEDO RJ–Grosse Pointe, Michigan	
15:20	3347	<b>Metastasising Malignant Eccrine poroma masquerading as Basal Cell Carcinoma</b> ARIF F, WEIR R–Stockport, London	

Fenix I	<b>Free papers : Cornea 4 - Refractive Surgery and Contact Lenses</b>		14:00 – 15:30
FP	Linda MÜLLER, Jean-Jacques GICQUEL		
14:00	3351	<b>LASEK vs LASIK to correct high myopia</b> TEUS MA, SÁNCHEZ JM, GIL R, ARRANZ M, ORTEGA M–Madrid	
14:12	3352	<b>Comparative study of silicone and non silicone hydrogel soft contact lenses used as bandage after LASEK</b> GIL R, ARRANZ E, HERNÁNDEZ-VERDEJO JL, FUENTES I, TEUS MA–Madrid	
14:24	3353	<b>Changes in retinal nerve fiber layer thickness induced by LASIK surgery</b> ARRANZ E, ROMÁN JM, MARINA C, ALVAREZ M, TEUS MA–Madrid	
14:36	3354	<b>The Nature and Fate of Tear Lipids in Contact Lens Wear</b> <i>rf</i> MANN A, CAMPBELL D, GRIFFITH G, TIGHE B–Birmingham	
14:42	3355	<b>Visual recovery following PRK using corneal epithelium brushing and alcoholic dehydration : a confocal microscopy study</b> <i>rf</i> PICCIRILLO V, DI NUZZO A, RAO V–Maddaloni	
14:48	3356	<b>Influence of multipurpose solutions on the protein composition of the tear film</b> <i>rf</i> GRUS FH, BOZKURT N, PFEIFFER N–Mainz	
14:54	3357	<b>Frictional and lubricity changes in contact lenses during wear</b> <i>rf</i> MAHOMED A, NASSO M, TIGHE BJ–Birmingham	
15:00	3358	<b>Novel Ophthalmic Biomaterials</b> <i>rf</i> MAHOMED A, HENLEY C, TIGHE BJ–Birmingham	
15:06	3359	<b>Silicone Hydrogels: Trends in Products and Properties</b> <i>rf</i> FRANKLIN V, ROSS G, NASSO M, LYDON F, TIGHE B–Birmingham	

Fenix III	<b>Pathogenesis and prevention of diabetic cataract</b>		14:00 – 15:30
SIS	Kavita HEGDE, Shambhu D. VARMA		
14:00	3361	<b>Mechanism of polyol pathway-induced acute and slow-developing diabetic cataracts</b> CHUNG SSM, CHAN AWH, CHUNG SK–Hong Kong	
14:18	3362	<b>Glycemic and Oxidative stress in the Lens. Implications on Cataract Formation in diabetes</b> HEGDE KR, VARMA SD–Baltimore	
14:36	3363	<b>Genetic Studies of Aldo-Keto Reductases and Diabetic Eye Disease</b> PETRASH M, CHANG Q–Saint Louis	
14:54	3364	<b>Non-structural functions of crystallin</b> BHAT S–Los Angeles	
15:12	3365	<b>Loss of beta-crystallin chaperone activity, a probable cause for diabetic cataract</b> ABRAHAM EC–Little Rock	

**Poster session**16:30 – 17:30  
Neptuno**Glaucoma, Lens and Cataract, Molecular Biology / Genetics / Epidemiology, Pathology / Oncology**

Herbert REITSAMER, Volkan DAYANIR, Ingeborg STALMANS, Rafael I. BARRAQUER, Ralph MICHAEL, Marcela VOTRUBA, Rita VAN GINDERDEUREN, Jan Ulrik PRAUSE

Gemini I	<b>Workshop : The assessment of visual functions in people with sight loss</b>		17:30 – 19:00
Workshop	Ian BAILEY, Jonathan JACKSON		
17:30	3411	Visual acuity test chart designs, testing procedures and scoring methods, and their effects on acuity scores BAILEY I, JACKSON J–Berkeley, Belfast	
17:48	3412	Techniques for, and limitations of visual acuity measurements in different categories of low vision BAILEY I, JACKSON J–Berkeley, Belfast	
18:06	3413	Visual field measurement and the special techniques required for the assessment the functional abilities of low vision patients BAILEY I, JACKSON J–Berkeley, Belfast	
18:24	3414	Methods for measuring contrast sensitivity and applying the measurements of contrast thresholds and response efficiency to predictions of functional abilities BAILEY I, JACKSON J–Berkeley, Belfast	
18:42	3415	Methods used to assess reading performance and near visual acuities BAILEY I, JACKSON J–Berkeley, Belfast	

Gemini III	<b>Advancements in the medical management of glaucoma</b>		17:30 – 19:00
SIS	Anastasios G.P. KONSTAS		



17:30	3421	24-hour IOP control with Travoprost KONSTAS AGP–Thessaloniki	
17:45	3422	Efficacy and safety of carbonic anhydrase inhibitors as adjunctive therapy to a PGA CARASSA RG–Milan	
18:00	3423	Concomitant use of Travatan and Azopt vs. the fixed Latanoprost/Timolol combination GARCIA-FEIJOO J–Madrid	
18:15	3424	Azopt in adjunct therapy with Travatan vs Travatan monotherapy FRANKS W–London	
18:30	3425	Clinical utility and update of fixed combinations DENIS PH–Lyon	

Pegasus	<b>Free papers : Retina 1 - Antiangiogenic treatments</b>		17:30 – 19:00
FP	Tony ADAMIS, Hansjürgen T. AGOSTINI		

17:30	3431	Involvement of active gelatinase B/matrix metalloproteinase-9 in vitreous hemorrhagic transformation of proliferative diabetic retinopathy ABU EL ASRAR AM, DESCAMPS FJ, MARTENS E, KANGAVE D, STRUYF S, GEBOES K, OPDENAKKER G–Riyadh, Leuven	
17:42	3432	Immunoreactive ET-1 in the vitreous humour and epiretinal membranes of patients with proliferative diabetic retinopathy ROLDAN-PALLARES M, ROLLIN R, MARTINEZ-MONTERO JC, FERNANDEZ-CRUZ A, BRAVO-LLATA C, FERNANDEZ-DURANGO R–Madrid	
17:54	3433	Cytokine gene polymorphism in retinal detachment patients with and without proliferative vitreoretinopathy. Preliminary study PASTOR JC, SANABRIA MR, GARROTE JA, TELLERIA JJ, GARCIA MT–Valladolid	
18:06	3434	Inhibition of in vitro angiogenesis by PI-88 alone or in combination with steroids FERRO V, CHAPMAN P, MCDONALD L, HAMMOND E, LI C–Brisbane, Dublin	
18:18	3435	Reduced retinal neovascularization in mice after intravitreal injection of monomeric soluble EphB4 LANGE CAK, EHLKEN C, SCHAFFNER F, MARTIN G, HANSEN LL, AUGUSTIN HG, AGOSTINI HT–Freiburg	
18:30	3436	PI-88: a potent angiogenesis inhibitor with potential for treatment of back-of-the-eye diseases CHAPMAN P, FERRO V, PARISH C, FREEMAN C–Dublin, Brisbane, Canberra	

Vega	<b>OOG 4</b>	17:30 – 19:00
Joint M.	Edoardo MIDENA, Laurence DESJARDINS	

17:30	OOG Business meeting
18:00	Organisation
18:30	Protocols

Fenix I	<b>Free papers : Lens and Cataract 1 - Clinical</b>	17:30 – 19:00
FP	Jochen GRAW, Per SÖDERBERG	

17:30	3451	A complete, open-access, evidence-based and objective system of analysis of posterior capsular opacification ASLAM TM, PATTON N, DHILLON B, GRAHAM J—Manchester, Edinburgh
17:42	3452 <i>rf</i>	Lens optical quality: the area under the modulation transfer function correlates with visual acuity SHAMS PN, DAVIES NP, WEALE RA—London
17:48	3453 <i>rf</i>	3D images of cataract surgery: a new telemedicine and didactic tool LIBONDI T, CRICELLI R, CAPUTO S, ZEPPA L, GIACOIA A, COLONNA G—Napoli, Avellino
17:54	3454	Selecting patients undergoing cataract surgery according to their sensitivity to pain GOMBOSS K, JAKUBOVITS E, SALACZ GY, NAGY ZS—Budapest
18:06	3455 <i>rf</i>	Variation in the theatre team and its impact on the outcome of complicated cases BAYLIS OJ, ADAMS W, FRASER SG—Sunderland
18:12	3456 <i>rf</i>	Intraoperative breakage of the mushroom manipulator tip during phacoemulsification PELOSINI L, RICHARDSON EC, GOEL R, HUGKULSTONE CE—Sidcup
18:18	3457 <i>rf</i>	Effect of Sodium Hyaluronate (Ophthalin®) and Hydroxypropylmethylcellulose (HPMC-Ophtal®) on Corneal Endothelium, Central Corneal Thickness, and Intraocular Pressure after Phacoemulsification VOROS GM, RESSINIOTIS T, RAY-CHAUDHURY N, SUTHERLAND S, MITCHELL K, FIGUEIREDO FF—Newcastle upon Tyne
18:24	3458	Physiopathology of the lens capsule after implantation of an intraocular lens DE KEYZER KHMH, LEYSEN I, TASSIGNON MJ—Antwerp

Fenix III	<b>Workshop: Measurement of accommodation</b>	17:30 – 19:00
Workshop	Adrian GLASSER, Ralph MICHAEL	

17:30	3461	Introduction to measurement of accommodation GLASSER A—Houston
17:45	3462	Optical techniques to measure natural accommodation SCHAEFFEL F—Tübingen
18:00	3463	Accommodation Measurement with Shin-Nippon Autorefractors WOLFFSOHN JS—Birmingham
18:15	3464	Wavefront Measurement of Accommodation LOPEZ-GIL N—Murcia
18:30	3465	Hands-on practice: Accommodation measurement GLASSER A, SCHAEFFEL F, MICHAEL R, LOPEZ-GIL N, WOLFFSOHN JS—Houston, Barcelona, Murcia, Birmingham

<b>19:00 – 19:30 Business Meetings of the scientific sections:</b>	<ul style="list-style-type: none"> <li>- Anatomy / Cell Biology</li> <li>- Cornea / Ocular Surface</li> <li>- Glaucoma</li> <li>- Immunology / Microbiology</li> <li>- Lens and Cataract</li> <li>- Molecular Biology / Genetics / Epidemiology</li> <li>- Neuro-ophthalmology / Strabismology</li> <li>- Pathology / Oncology</li> <li>- Physiology / Biochemistry / Pharmacology</li> <li>- Retina / Vitreous</li> <li>- Vision Sciences / Electrophysiology / Physiol. Optics</li> </ul>
<b>Agenda</b>	
1. Report of the scientific officer	
2. Report of the Programme Secretary	
3. Next year's meeting:	
• nomination of a section programme secretary	
• proposals of Special Interest Symposia	
4. Comment on the EVER activities	
5. Other business	
In addition to the agenda, the sections <i>Immunology / Microbiology</i> and <i>Physiology / Biochemistry / Pharmacology</i> will nominate candidates for scientific officer.	

## GLAUCOMA

- 301 **Ability of the OCT to detect patients with preperimetric glaucoma**  
LALIENA SANTAMARÍA JL, PARDIÑAS BARÓN N, GARCÍA ABELLÁN V, GARCÍA FEJOO J, SÁNCHEZ-CANO A, PÉREZ OLIVAN S—Zaragoza, Madrid
- 302 **Quantification of neuroretinal rim loss using digital planimetry in long-term follow-up of normals and patients with ocular hypertension**  
LAEMMER R, SCHROEDER S, JUENEMANN AG, VIESTENZ A, MARDIN CY—Erlangen
- 303 **Comparison of two cornea compensation methods in scanning laser polarimetry on eyes with atypical polarisation pattern**  
TÓTH M, VARGHA P, HOLLÓ G—Budapest
- 304 **Morphometric parameters of scanning laser tomograph (HRT-II) and scanning laser polarimetry (GDx-VCC) to discriminate between normal and glaucomatous eyes**  
MILANO G, SERRA U, MACERI C, TISO C, SCATASSI I—Pavia
- 305 **A prospective long-term study about morphological and functional test for the early diagnostic of glaucoma**  
GARCIA ABELLAN V, PARDIÑAS BARON N, LALIENA SANTAMARIA JL, FERNANDEZ LAR-RIPA S, PEREZ OLIVAN S, PABLO JULVEZ L, MARTINEZ DE LA CASA JM—Zaragoza, Madrid
- 306 **Correlation between retinal nerve fiber layer measurements performed by means of optical coherence tomography and scanning laser polarimeter GDx VCC**  
FERRERAS A, POLO V, LARROSA JM, PAJARIN AB, PUEYO V, HONRUBIA FM—Zaragoza
- 307 **Heidelberg retina tomography versus optical coherence tomography in the optic nerve head analysis: a correlation study**  
FERRERAS A, LARROSA JM, POLO V, PAJARIN AB, MASANA C, HONRUBIA FM—Zaragoza
- 308 **Clinical ability of Heidelberg Retinal Tomograph II to diagnose early glaucoma**  
PARDIÑAS BARON N, LALIENA SANTAMARIA JL, GARCÍA ABELLAN V, PABLO JULVEZ L, HONRUBIA LOPEZ F—Zaragoza
- 309 **Retinal nerve fiber layer assessment by means of Optical Coherence Tomography in glaucoma diagnosis**  
MAYORAL F, POLO V, FERRERAS A, LARROSA JM, LOPEZ MJ, PUEYO V, SANCHEZ-CANO A, HONRUBIA FM—Zaragoza
- 310 **Analysis of optic disc in normal subjects, glaucoma suspects and glaucoma patients with Confocal Scanning Laser (HRT II)**  
ALIAS E, LARROSA JM, FERRERAS A, POLO V, LOPEZ MJ, BORQUE E, MAYORAL F, HONRUBIA FM—Zaragoza
- 311 **Correlation between perimetric indices of conventional automated perimetry and structural parameters obtained by means of OCT, HRT and GDx**  
LOPEZ PEÑA MJ, LARROSA JM, POLO V, FERRERAS A, PUEYO V, BORQUE E, ALIAS E, HONRUBIA FM—Zaragoza
- 312 **Diagnostic ability of analysis tools for detection of glaucoma with the Confocal Scanning Laser Tomograph (Heidelberg Retina Tomograph II)**  
BORQUE E, FERRERAS A, POLO V, LARROSA JM, ALIAS E, MAYORAL F, SANCHEZ-CANO A, HONRUBIA FM—Zaragoza
- 313 **Diagnostic value of the Stratus OCT Optical Coherence Tomograph, Heidelberg Retina Tomograph (HRT II) and GDx VCC Scanning Laser Polarimeter to detect structural damage in glaucomatous eyes**  
PUEYO V, POLO V, LARROSA JM, FERRERAS A, MAYORAL F, BORQUE E, SÁNCHEZ-CANO A, HONRUBIA FM—Zaragoza
- 314 **Dynamic Contour Tonometry after intraocular surgery**  
KAMPPETER BA, JONAS JB—Mannheim
- 315 **Agreement between a new tonometer-ICARE- and Goldmann applanation**  
TONINI MT, SAVY OS, RENARD ER, THURET GT, CHIQUET CC, MOUILLON MM, ROMANET JPR—Grenoble
- 316 **Comparison of the ICare® rebound tonometer with the Goldmann tonometer in a normal population**  
FERNANDES P, DÍAZ-REY JA, QUEIRÓS A, GONZALEZ-MEIJOME JM, JORJE J—Braga
- 317 **The impact of ocular perfusion pressure in the retrobulbar blood flow**  
MARTÍNEZ-GARCÍA A, SÁNCHEZ-SALORIO M—Santiago de Compostela
- 318 **Pigmentary Glaucoma – Ultrasound Biomeicroscopy Imaging (UBM) before and after laser iridotomy**  
DA COSTA SA, COELHO A, MAIA SECO J, PRIOR FILIPE H, QUINTAO T, CASTANHEIRA-DINIS A—Lisbon
- 319 **Structural changes of the anterior chamber angle in primary congenital glaucoma with respect to normal development**  
SALAZAR JJ, RAMIREZ AI, DE HOZ R, ROJAS B, RAMIREZ JM, FERNANDEZ Y, TRIVIÑO A—Madrid
- 320 **Glaucoma awareness and detection in African-Caribbeans: 'Talking the talk'**  
CROSS V, SHAH P, BATIVALA R, SII F—Birmingham
- 321 **Is Primary Open-Angle Glaucoma influenced by the ambient temperature?**  
WEALE RA—London
- 322 **A Comparison of Travatan® and Cosopt® Therapy in Patients with Open Angle Glaucoma or Ocular Hypertension**  
SUZUKI JUNIOR ER, MEIRELLES LF, FIGUEIREDO CRL, AGOSTINI NETTO J, BATISTA WD—Belo Horizonte
- 323 **IOP-REDUCING EFFECT OF TRAVATAN® VS XALCOM® IN PATIENTS PREVIOUSLY TREATED WITH TOPICAL -BLOCKERS**  
FRANKS W, RENARD JP—London, Paris
- 324 **Effect of latanoprost on the anterior chamber depth and its dynamics in patients with glaucoma or ocular hypertension**  
GUTIERREZ C, TEUS MA—Madrid
- 325 **Argon laser trabeculoplasty versus selective laser trabeculoplasty: short term outcome**  
VAN DE VEIRE S, ZEYEN T, STALMANS I—Leuven
- 326 **Lasering the trabecular meshwork and limbal veins in adult rats results in ocular hypertension and retrograde degeneration of retinal ganglion cells**  
VIDAL-SANZ M, MAYOR S, RAMÍREZ AI, TRIVIÑO A, SALAZAR JJ, RAMÍREZ JM, SALINAS M, VILLEGAS-PÉREZ MP—Murcia, Madrid
- 327 **Our experience of using semiconductor laser for the treatment of neovascular glaucoma after diabetic retinopathy in Armenia**  
BUNIATYAN IRINA Y—Yerevan
- 328 **Trans-scleral Diode Laser Cyclophotocoagulation treatment for refractory glaucoma**  
PHERWANI AA, GREGORY ME, SIM K—Birmingham, Stoke on Trent
- 329 **A Little Bit of ReGAE (Research into Glaucoma and Ethnicity) – The Story So Far with Trabeculectomy and Mitomycin C**  
SHAH P, SII F, LOCKWOOD A—Birmingham
- 330 **Implant Ex-PRESS miniature glaucoma under a scleral flap**  
CARNOVALE SCALZO G, SCORCIA V, BRUZZICHESSI D, CATALANO C, SCORCIA G—Catanzaro
- 331 **Pneumatic Trabeculoplasty (PNT): our experience**  
PESCE G, FRATTO M, SCHIAVELLO M, SCORCIA V, BRUZZICHESSI D, CARNOVALE SCALZO G—Catanzaro
- 332 **Who Will Need Bleb Needling Revision with 5FU After Trabeculectomy with Mitomycin C?**  
SII F, SHAH P, LOCKWOOD A—Birmingham
- 333 **Safety and Efficacy of Trabeculectomy and Mitomycin C in Uveitic Glaucoma**  
LOCKWOOD A, SII F, CHIANG M, SHAH P—Birmingham, Brisbane
- 334 **Anterior Segment Optical Coherence Tomography of the Ex-PRESS miniature glaucoma implant**  
BIALLOSTERSKI C, DE BRUIN DM, AALDERS M, FABER DJ, DE JONG LAMS, VERBRAAK FD—Amsterdam
- 335 **Deep sclerectomy supplemented with 5 Fluorouracil**  
GUTIERREZ C, TEUS MA—Madrid
- 336 **Preclinical assessment of a radioactive implant for glaucoma filtering surgery – preliminary results**  
PICHLER A, HELD A, SCHUBERT M, ASSMANN W, LANZL I—Munich, Munich-Garching
- 337 **Central corneal pachymetry in children with congenital glaucoma after trabeculectomy**  
*rf* OBERACHER-VELTEN I, LORENZ B—Regensburg
- 338 **Retrobulbar hemodynamics in asymmetric glaucoma**  
*rf* REMKY A, PLANGE N, KAUP M, AREND O—Aachen

- 339 **A new scoring system for giant cell arteritis (GCA) - Can the result of a temporal artery biopsy (TAB) be predicted?**  
*rf*  
NESTEL AR, WHITTAKER KW, GIBSON RA, ENOCH BE—Barnstaple, Devon
- 340 **Intraocular Pressure Lowering effect of dorzolamide/timolol fixed combination in non-responder glaucoma patients to prostaglandin analogues/prostamides**  
*rf*  
MARTÍNEZ-GARCÍA A, SÁNCHEZ-SALORIO M—Santiago de Compostela
- 341 **Safety and efficacy of the Optonol DS version microtube implanted during deep sclerectomy in POAG patients: preliminary results**  
*rf*  
POURNARAS J-A C, MERMOUD A—Lausanne

## LENS and CATARACT

- 342 **The feasibility of implantation of pseudophakic wide angle miniature telescope in eyes with ruptured lens capsular bag**  
ROSNER M, SACHS D, ZIV H, BELKIN M—Tel-Hashomer
- 343 **Black opaque intraocular lens implantation in three patients: diagnoses leukocoria; loss of fusion; and alternating hypotropia with image delay**  
DUBOIS VDJP, MAVRIKAKIS I, VICKERS S, LIU CSC—Brighton, East Grinstead
- 344 **Correlation between IOL materials and secondary cataract. A flare meter study**  
BRAVETTI GO, CELLINI M, BENDO E, CAMPOS EC—Bologna
- 345 **Quality of vision after AcrySof ReSTOR multifocal intraocular lens implantation**  
CHIAM P, CHAN J, KASABY H E, AGGARWAL R K—Southend, London
- 346 **Capsular shrinkage after phacoemulsification and implant surgery**  
KULJACA Z, DZAKOVIC N, RADOVIC N, IGUNJATOVIC Z, BEKO M—Belgrade
- 347 **Metabolic differences in rat lens regions after UV-B irradiation analysed by HR-MAS 1H NMR spectroscopy**  
TESSEM MB, BATHEN FT, LÖFGREN S, MODY V, MEYER L, DONG X, SÖDERBERG PG, MIDELFART A—Trondheim, Stockholm
- 348 **Lens optical quality: the area under the modulation transfer function correlates with visual acuity**  
*rf*  
SHAMS PN, DAVIES NP, WEALE RA—London
- 349 **3D images of cataract surgery: a new telemedicine and didactic tool**  
*rf*  
LIBONDI T, CRICELLI R, CAPUTO S, ZEPPA L, GIACOIA A, COLONNA G—Napoli, Avellino
- 350 **Variation in the theatre team and its impact on the outcome of complicated cases**  
*rf*  
BAYLIS OJ, ADAMS W, FRASER SG—Sunderland
- 351 **Intraoperative breakage of the mushroom manipulator tip during phacoemulsification**  
*rf*  
PELOSINI L, RICHARDSON EC, GOEL R, HUGKULSTONE CE—Sidcup
- 352 **Effect of Sodium Hyaluronate (Ophthalin®) and Hydroxypropylmethylcellulose (HPMC-Ophthal®) on Corneal Endothelium, Central Corneal Thickness, and Intraocular Pressure after Phacoemulsification**  
*rf*  
VOROS GM, RESSINIOTIS T, RAY-CHAUDHURY N, SUTHERLAND S, MITCHELL K, FIGUEIREDO FF—Newcastle upon Tyne

## MOLECULAR BIOLOGY / GENETICS / EPIDEMIOLOGY

- 353 **Tridimensional representation of KID syndrome mutations in GJB2 gene: from structure to function**  
MENNECIER G, GICQUEL JJ, DIGHIERO P, MESNIL M—Poitiers
- 354 **Fine mapping of an autosomal dominant cone-rod dystrophy (CORD5) to a 2.61 Mb region on 17p13.1-p13.2**  
KÖHN L, MOHARER J, HARALDSSON S, SANDGREN O, GOLOVLEVA I—Umeå
- 355 **No association between primary open angle glaucoma and WAF1 gene in Caucasians**  
RESSINIOTIS T, VOROS GM, GRIFFITHS PG, KEERS SM, CHINNERY PF, BIRCH M—Newcastle upon Tyne
- 356 **Aey12, a new mutation affecting the early eye development**  
PUK O, LÖSTER J, BECKERS J, GRAW J—Neuherberg
- 357 **Ocular components data in young adults and their correlation with the refractive error**  
QUEIROS A, GONZALEZ-MEIJOME J, JORGE J, FRANCO S—Braga

- 358 **An automated system of measuring decentration of anterior segment structures from geometric central axis**  
ASLAM T M, GUPTA A, ROSE C, CHARLES S J—Manchester
- 359 **Prospective Study on the Prevalence of Refractive Conditions in the North of Portugal**  
QUEIROS A, JORGE J, GONZALEZ-MEIJOME J, FERNANDES P, ALMEIDA JB, PARAFITA MA—Braga, Santiago Compostela
- 360 **A Quick Look at the Lid Surgeries We Do**  
RAVINDRANATHAN R, TAHHAN M—West Bromwich
- 361 **Avulsion of the eyeball - a rare injury in childhood (case report)**  
VA'MOS R, FARKAS Á, SALACZ G—Budapest
- 362 **Homozygote cytokeratin 12 mutation in a Danish family with Meesmann's dystrophy**  
*rf*  
NIELSEN KN, ORNTOFT TFO, HJORTDAL JH, EHLERS NE—Aarhus
- 363 **Study of Primary Mutation and Clinical Features of Leber's Hereditary Optic Neuropathy in Chinese Patients**  
*rf*  
GUO X, WANG Y, JIA X—Guangzhou
- 364 **To ascertain the prevalence of poor vision which exists in boys at a prestigious school in a developing country (Trinidad)**  
*rf*  
DWARIKA D, BHOLA RM, SEEMONGAL DASS R, EMAMALIE S—Birmingham, Sheffield, Trinidad
- 365 **Ocular complications and evaluation of quality of life in patients after Stevens-Johnson and Lyell syndromes**  
*rf*  
GUEUDRY J, BINAGHI M, SOUBRANE G, ROUJEAU J-C, BRASSEUR G, MURAINÉ M—Rouen, Créteil
- 366 **Missed metal Foreign Bodies**  
*rf*  
SKINNER KC, CHRONI FC, MERRICK CD, GREGORY PTS—St-Leonards-on-Sea
- 367 **OPHTEC Iris Reconstruction Lens in Ocular Trauma**  
*rf*  
KULJACA Z, IGUNJATOVIC ZI, DZAKOVIC N, PAVLOVIC S—Belgrade, Giessen

## PATHOLOGY / ONCOLOGY

- 368 **Ciliary epithelial cells estimation during experimental diabetes**  
MACHOWICZ-MATEJKO E—Lublin
- 369 **Scleritis and Bilateral Exudative Retinal Detachments as a First Presentation of Metastatic Carcinoma**  
WRIDE NK, COTTRELL DG, BIRCHALL D, PANDIT RJ—Newcastle-upon-Tyne
- 370 **Experimental study of the survival of metastatic cancer cells on organ cultured corneas: cell tracking and molecular biology**  
DEB N, ABSI L, DUMOLLARD JM, CAMPOS-GUYOTAT L, GAIN P, THURET G—Saint-Etienne
- 371 **Palpebral basal cell carcinoma: relation between 34-betaE12, bcl-2 and Ki-67 expression**  
MISIUK HOJLO M, WOZNIK ZM, BARANCEWICZ-LOSEK M, SZYBEJKO-MACHAJ G, MAJ J, BIENIEK A—Wroclaw
- 372 **Use of Mitomycin C (MMC) in the treatment of primary acquired melanosis of the conjunctiva**  
MISSOTTEN GS, DE KEIZER RJW, DE WOLFF-ROUENDAAL D—Leiden
- 373 **Effects of the Raf inhibitor BAY43-9006 in human uveal melanoma cell**  
MOURIAUX F, CALIPEL A, GLOTIN AL, MASCARELLI F—Caen, Paris
- 374 **Individual calibration of sources in episcleral brachytherapy**  
DE FRUTO BARAJA JM, SAORNIL MA, ALMARAZ A, LOPEZ-LARA F, DEL CASTILLO A, GIRALDO A—Valladolid
- 375 **Transpupillary thermotherapy in choroidal melanoma with vitreous haemorrhage as its first clinical sign: case report**  
VIDE ESCADA EICKMANN A, NASCIMENTO J, CASTANHEIRA-DINIS A—Lisboa
- 376 **Detection of uveal melanoma cells in peripheral blood using the melan-A antigen**  
MORILLA A, OREA M, BLANCO G, SAORNIL MA, ORDOÑEZ JL, MENDEZ MC, BURNIER JR MN—Valladolid, Montreal



*ever 2005*

**Saturday 8 October**



Gemini I	<b>Keratoprosthesis I</b>	08:30 – 10:00
SIS	Christopher LIU	

08:30	4111	How to choose a keratoprosthesis when you need one LIU C–Brighton
08:45	4112	Update on Brighton OOKP results AINSWORTH G, PAUL B, TANDON R, HEROLD J, THORP S, LIU C–Brighton, New Delhi
09:00	4113	Results of the champagne-cork keratoprosthesis: preliminary data from a second centre in India TANDON R, SHARMA N, VAJPAYEE RB, GARG SP, SINGH I–New Delhi, Amritsar
09:05	4114	Imaging of Osteo-odonto-keratoprosthesis (OOKP) by High Resolution Computed Tomography (HRCT) after stage 1 and prior to Stage 2 TANDON R, SHARMA R, ROYCHOWDHARY A, VASHISHT N, SHARMA N, LIU C–New Delhi, Brighton
09:10	4115	Boston Keratoprosthesis after Herpetic Keratitis and in Aniridia KHAN BF, DOHLMAN CH–Boston, MA
09:25	4116	Blockage of Glaucoma Shunts in the Boston Keratoprosthesis: Relationship to Lens Status COLBY KA, DOHLMAN CH–Boston, MA

Gemini III	<b>Intraocular pressure and corneal thickness</b>	08:30 – 10:00
SIS	Volkan DAYANIR	



08:30	4121	Applanation Tonometry: its use, corneal sources of error, and clinical implications DAYANIR V–Aydin
08:50	4122	Adjusting Goldmann Tonometry for corneal sources of error KUBE T–Freiburg
09:10	4123	Dynamic contour tonometry: is the "gold standard" for intraocular pressure measurement changing? PACHE M–Freiburg
09:30		Discussion

Pegasus	<b>Free papers : Retina 2 - Macular pigments - Gene expression</b>	08:30 – 10:00
FP	Daniel PAULEIKHOFF	

08:30	4131	Macular Pigment Measurement Using Motion Nulling MELLERIO J, WEST P–London, Rochester
08:42	4132	Imbalance of Extracellular Matrix turnover in Age-related macular degeneration SIVAPRASAD S, CHAU KY, LUTHERT PJ, BAILEY TA, CHONG NHV–London, Bedfordshire
08:54	4133	Low density lipoprotein (LDL) and its oxidized form induce early age related macular degeneration characteristics in vitro. WELGE-LÜBEN UC, KOOK D, KAMPIK A–Munich
09:06	4134	Global gene expression in normal RPE and in CNV-RPE determined by SAGE MARTIN G, AGOSTINI HT, HANSEN LL–Freiburg
09:18	4135	In vitro AAV gene transfer optimisation on ARPE cells KOCH P, DE GREEF S, BRUYNS C, CASPERS L, TENENBAUM L, WILLERMAIN F–Brussels
09:30	4136 <i>rf</i>	Multispectral Fundus Analysis CALCAGNI A, STYLES IB, CLARIDGE E, ORIHUELA-ESPINA F, GIBSON JM–Birmingham
09:36	4137 <i>rf</i>	Zinc in Drusen PETO T, LENGYEL I, FREDERICKSON C, VAN KUIJK E–London, Galveston

Vega **Free papers : Retina 3 - Diagnostic techniques** 08:30 – 10:00  
 FP Charles RIVA, Jean-Jacques DE LAEY

08:30	4141	Multimodal macula mapping: study for rigid, perspective and deformable image registration. BAPTISTA P, BERNARDES R, CUNHA-VAZ J—Coimbra
08:42	4142	Artefacts in Optical Coherence tomography (OCT) imaging of the retina STRAUSS RW, THIEL MJ, ULBIG MW, KAMPIK A, NEUBAUER AS—Munich
08:54	4143	OCT in patients with X-linked Retinoschisis MENKE MN, NAKAMURA H, HIROSE T—Leipzig, Boston
09:06	4144	Retinal thickness measurements: RTA II vs Stratus OCT in healthy subjects NUNES S, BERNARDES R, BAPTISTA P, CUNHA-VAZ J—Coimbra, Portugal, Coimbra
09:18	4145	Implementing a Colour-Coded Scheme for Earmarking Retinal Changes in a Sequence of Digital Colour Fundus Photographs FERREIRA J, BERNARDES R, BAPTISTA P, CUNHA-VAZ J—Coimbra
09:30	4146	Non-invasive Real-time Retinal Temperature Determination during Laser Treatments BRINKMANN R, KANDULLA J, ELSNER H, ROIDER J, BIRNGRUBER R—Lübeck, Kiel

Fenix I **Biopsy of intraocular tumours** 08:30 – 10:00  
 SIS Edoardo MIDENA, Jan Ulrik PRAUSE

08:30	4151	Biopsy Of Intraocular Tumors AUGSBURGER JJ—Cincinnati, OH
08:48	4152	Transvitreal choroidal biopsy of intraocular neoplasms. A + 10 year follow-up of a 10 year consecutive series of biopsied patients JENSEN PK, SCHERFIG E, HEEGAARD S, PRAUSE JU—Copenhagen
09:06	4153	In Vivo Cytogenetic Characterization of Choroidal Melanoma before Brachytherapy MIDENA E—Padova
09:24	4154	Choroidal Tumor Biopsy with 25-gauge Vitrector DAMATO B, SEN J, GROENEWALD C, HISCOTT P, SMITH P—Liverpool
09:42	4155	Cytologic and Cytogenetic Characteristics of Intraocular Lymphomas COUPLAND SE, HUMMEL M, STEIN H—Berlin

Fenix III **ARVO session : Successfully Conducting International Research** 08:30 – 10:00  
 SIS Sally ATHERTON



08:30		<i>Introduction</i>
08:35	4161	Finding Opportunities for Collaboration Between Researchers in the US and Other Countries ATHERTON S—Augusta, GA
09:00	4162	Funding Mechanisms for Collaboration Between Researchers in the US and Other Countries McNICOL LA
09:25	4163	Navigating Problems and Pitfalls of Collaborating with US Researchers KAUFMAN P—Madison, WI
09:50		<i>Final discussion</i>

**Keynote Lecture**

10:15 – 10:55  
 Fenix III

**Medical Therapy of Glaucoma in the Future: From Cell Culture to Clinic**

Paul L. KAUFMAN — Madison, Wisconsin  
 Introduction by Jost JONAS



Gemini I	<b>Keratoprosthesis II</b>	11:00 – 12:30
SIS	Christopher LIU	

11:00	4211	AlphaCor Outcomes Update HICKS CR–Nedlands
11:15	4212	Theoretical considerations for glaucoma tubes in KPro eyes BARTON K–London
11:30	4213	Role of mechanical stimulation in corneal tissue engineering THEN K–Birmingham
11:45	4214	Analysis of corneal epithelial cell adhesion & growth on poly (methyl methacrylate) PMMA after atmospheric plasma surface treatment MOORE JE, SMALL DM, MEENAN BJ, LIU C, DOWNES CS, MOORE CBT–Belfast, Coleraine, Jordanstown
12:00	4215	Smart materials for corneal replacements: natural, synthetic and hybrid biomaterials as instructive extracellular microenvironments GRIFFITH M, LI F, FARAJI H, BUECKERT D, LIU Y–Ottawa
12:15	4216	Selection and in vitro Evaluation of a Synthetic OOKP Support Frame TIGHE BJ, LLOYD AW, GREEN D, VIITALA R, FRANKLIN VJ, LIU CS–Birmingham

Gemini III	<b>Beyond IOP - Vascular aspects of glaucoma</b>	11:00 – 12:30
SIS	Ingeborg STALMANS	



11:00	4221	Autoregulation and glaucoma GUGLETA K–Basel
11:18	4222	Intraocular pressure fluctuations and variability of blood pressure and heart rate NEVES C, BETTENCOURT MJ, POSTOLACHE G, SILVA-CARVALHO L, ROCHA I–Lisbon
11:36	4223	Blood flow alterations in glaucoma HARRIS A–Indianapolis, IN
11:54	4224	Oxymetry of the optic nerve head STEFANSSON E, LACOUR M, JENSEN P K, PEDERSEN D B, KIILGAARD JF, HOVE M, BENEDIKTSSON JA, HALLDORSSON GH, KARLSSON RA, HARDARSSON SH, BEACH JM, EYSTEINSSON T–Reykjavik, Copenhagen
12:12	4225	Drug-induced ocular blood flow alterations RECHTMAN E–Haifa

Pegasus	<b>Free papers : Retina 4 - PDT - Triamcinolone</b>	11:00 – 12:30
FP	Constantin POURNARAS, Albert AUGUSTIN	

11:00	4231	Predictive factors for predominantly classic choroidal neovascular membrane enlargement following photodynamic therapy. FLETCHER EC, KHAN J, MENON G, CHONG NHV–London, Surrey
11:12	4232	Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes TATAR O, ADAM A, SHINODA K, VÖLKER M, LAFAUT B, BARTZ-SCHMIDT KU, GRISANTI S–Tuebingen, Tokyo, Bruges
11:24	4233	Inter-eye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularisation after unilateral intravitreal injection of triamcinolone acetonide JONAS JB, SPANDAU UH, HARDER B, VOSSMERBAUEMER U, KAMPPETER BA–Mannheim
11:36	4234	Photodynamic therapy and intravitreal triamcinolone at high doses to treat exudative age related macular degeneration: one year outcome. MONTERO-MORENO JA, RUIZ-MORENO JM, BARILE S–Alicante
11:48	4235	Polypoidal choroidal vasculopathy in Korean patients with large submacular hemorrhage LEE SC, YOON JS, LEE JH, KOH HJ, KWON OW–Seoul
12:00	4236 <i>rf</i>	Morphological Features of Classic and Occult subfoveal Choroidal Neovascular Membrane using OCT -An aid to diagnosis ADEWOYIN TA, KHAN J, CHONG NHV–London
12:06	4237 <i>rf</i>	Photodynamic therapy versus surgical removal from choroidal neovascularisation in high myopia HERA R, VINH MOREAU V, GONZALVEZ B, MILLET JY, ROMANET JP, MOUILLON M–Grenoble

Vega	<b>ISCEV</b>	11:00 – 12:30
Joint M.	Colin BARBER	

11:00	4241	<b>Electrophysiologic testing in unexplained visual loss</b> LAM BL–Miami, FL
11:15	4242	<b>Functional and anatomical imaging of the retina: combining OCT and SLO imaging with multifocal ERG</b> KEATING D, DUDGEON S, PARKS S–Glasgow
11:30	4243	<b>Electrophysiology in relation to autofluorescence imaging in retinal dystrophies</b> HAWLINA M–Ljubljana
11:45	4244	<b>The effect of light as a stimulus and light as an environment on retinal function</b> LACHAPPELLE P, RUFIANGE M, BEAULIEU C, DUMONT M–Montréal, Québec
12:00	4245	<b>Genetic ophthalmology &amp; electrophysiology: inseparable conjoined twins</b> LEROY BP–Ghent
12:15	4246	<b>Electrophysiology and inflammatory eye disease</b> HOLDER GE–London

Fenix I	<b>New concepts in ocular &amp; adnexal lymphoma</b>	11:00 – 12:30
SIS	Maria Antonia SAORNIL ALVAREZ, Rita VAN GINDERDEUREN	

11:00	4251	<b>Introduction</b> SAORNIL M, VAN GINDERDEUREN R
11:05	4252	<b>Primary Retinal Lymphoma</b> BURNIER MN, ODASHIRO AN, MARSHALL JC–Montreal
11:20	4253	<b>Histopathological findings, prognostic factors and differential diagnosis of lymphoproliferative lesions of the ocular adnexa</b> COUPLAND SE–Berlin
11:35	4254	<b>Conjunctival MALT Lymphomas</b> VAN DER VALK P–Amsterdam
11:50	4255	<b>Lacrimal System Lymphomas</b> PRAUSE JU, SJÖ L, HEEGARD S–Copenhagen
12:05	4256	<b>New Therapeutic Approaches in Ocular and adnexal Lymphomas</b> DECAUDIN D–Paris

Fenix III	<b>Free papers : Immunology / Microbiology 1 - Clinical &amp; Experimental uveitis</b>	11:00 – 12:30
FP	Uwe PLEYER, Tom MISSOTTEN	

11:00	4261	<b>Effects of SOCS-1 gene transfer in ARPE cells</b> WILLERMAIN F, KISMA N, DE GREEF S, KOCH P, CASPERS L, BRUYNS C–Brussels
11:12	4262	<b>CCR2 V64I polymorphism as a genetic risk marker of Behçet's associated uveitis</b> AHAD M A, MISSOTTEN T, LIGHTMAN S–London
11:24	4263	<b>Serum Prolactin Levels and Behçet Disease</b> <i>rf</i> PROENCA H, GONÇALVES C, FERREIRA C, MIRANDA M, CASTANHEIRA-DINIS A, MONTEIRO GRILLO M–Lisbon
11:30	4264	<b>Fluorophotometry in patients with chronic posterior uveitis treated with intravitreal injections of triamcinolone acetonide</b> THOMAS V, PATTE M, COULANGEON LM, BACIN F–Clermont Ferrand
11:42	4265	<b>Intravitreal Triamcinolone in patients with uveitic macular edema. A prospective Study</b> SCHMIDT S, RIEGER R, VELHAGEN KH, PLEYER U–Berlin
11:54	4266	<b>Aetiologic diagnosis in uveitis of childhood</b> BOGDANICI C, ROBU M, BRATU C, CRASMARU C–Iasi
12:06	4267	<b>Contribution of lumbar puncture and CSF analysis in the diagnosis of Vogt-Koyanagi-Harada disease</b> <i>rf</i> BOUCHENAKI N, HERBORT CP–Geneva, Lausanne

Gemini I		<b>Free papers : Lens and Cataract 2 - Molecular Biology / Biochemistry</b>	14:00 – 15:30
FP		Shambhu D. VARMA	
14:00	4311	Mapping of a recessive cataract mutation to rat chromosome 1 GRAW J, PRETSCH W–Neuherberg	
14:12	4312	Chromatin remodeling and crystallin gene regulation in vivo in lens CVEKLA, YANG Y, PIRITY M, STOPKA T, CHAUHAN BK, SKOULTCHI A–Bronx	
14:24	4313	Loss of Chaperone Function of Alpha-Crystallin: A Probable Cause of Diabetic Cataract ABRAHAM EC–Little Rock, AR	
14:36	4314	Inhibition of GSK-3 protects the lens against oxidative stress KARLSSON J-O, PETERSEN A, SOLTANPOUR Y–Göteborg	
14:48	4315	Regulation of intercellular communication in lens epithelial cells: the role of C-Terminus of connexin 43 GIRAO H, RAMALHO J, CATARINO S, PEREIRA P–Coimbra	

Gemini III		<b>Ocular Biomechanics</b>	14:00 – 15:30
SIS		Konstantin KOTLIAR	
14:00	4321	Biofluidmechanical simulation for age-dependent local retinal arterial reaction KOTLIAR KE, SCHILLING R, ANCIGER D, EINZINGER J, VILSER W, LANZL IM–Munich, Ilmenau	
14:20	4322	A reassessment of Fisher's spinning lens test BURD HJ, WILDE GS, JUDGE SJ–Oxford	
14:34	4323	Effect of Intravitreal Injections and Volume Changes on Intraocular Pressure – a Biomechanical Model MAIER M, LANZL IM, BAUER SM, FEUCHT N, FISCHER E, WINKLER VON MOHRENFELS C, LOHMANN C, KOTLIAR K–Munich, St.Petersburg	
14:48	4324	Biomechanical interrelation between the lamina cribrosa topography and the tone of the ciliary muscle in myopia RYABTSEVA AA, HOMJAKOVA EN, SERGUSHEV SG, SVETLOVA OV–Moscow, St.Petersburg	
15:02	4325	Study of Biomechanical Properties of the Sclera Using Different Methods IOMDINA EN–Moscow	
15:16	4326	Physiological and biomechanical principles of the hypotensive medical therapy in presbyopia KOSHITZ IN, KOTLIAR KE, ZASEEVA MV, SVETLOVA OV–St.Petersburg, Munich	

Pegasus		<b>Free papers : Retina 5 - Diabetic Retinopathy</b>	14:00 – 15:30
FP		Jose CUNHA-VAZ, Francesco BANDELLO	
14:00	4331	Results of a diabetic retinopathy screening programme in London PETO T, HARRIS N, LEUNG I, ANDREWS R–London	
14:12	4332	OCT findings in DM type 1 patients with minimal or no retinopathy VERBRAAK FD, VAN VELTHOVEN MEJ, SCHLINGEMANN RO, MICHELS BPJ, DE VRIES HH–Amsterdam	
14:24	4333	Intravitreal triamcinolone acetonide in the treatment of severe bilateral diabetic cystoid macular edema SUMMANEN PA, KYTÖ JP, LUMISTE E–Helsinki	
14:36	4334	Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal retinal telangiectasis YILMAZ G, GEDIK S, AYNACI B, AKKOYUN I, AKOVA Y–Ankara	
14:48	4335	Audit of diabetic referrals – Rationalising patient referrals via a three-tier system <i>rf</i> FLETCHER EC, ADEWOYIN T, CHONG NHV–London	
14:54	4336	Detection of associated ocular lesions during screening of diabetic retinopathy <i>rf</i> DEB-JOARDAR N, THURET G, GERMAIN N, GARCIN AF, MANOLI P, GAVET Y, ESTOUR B, GAIN P–Saint-Etienne	
15:00	4337	A two-year prospective study of mild nonproliferative retinopathy in subjects with diabetes type 2 undergoing intensive oral tritherapy. Progression of retinopathy under stabilized metabolic control <i>rf</i> DUARTE L, RIBEIRO ML, NUNES S, LOBO C, BERNARDES R, GERALDES E, FARIA DE ABREU JR, CUNHA-VAZ JG–Coimbra	
15:06	4338	Subtenon triamcinolone acetonide to treat diabetic macular edema <i>rf</i> CELLINI M, ZAMPARINI E, BRAVETTI GO, BELLUSCI C, CAMPOS EC–Bologna	

## Poster session

15:30 – 16:30  
Neptuno**Retina / Vitreous, Vision Sciences / Electrophysiol. / Physiol. Optic, Immunology / Microbiology**

Jean-Jacques DE LAEY, Werner SPILEERS, Marko HAWLINA, Uwe PLEYER

Vega	<b>Doctor I can't see in the dark</b>	14:00 – 15:30
SIS	John BARBUR, Graham HOLDER	

14:00	4341	Clinical and investigational approach to dark blindness HAWLINA M–Ljubljana, Slovenia
14:20	4342	Congenital Night Blindness LEROY BP–Ghent
14:40	4343	What limits normal visual performance in the dark? BARBUR JL–London
15:00	4344	Electrophysiological diagnosis in night blindness HOLDER GE–London

Fenix I	<b>Free papers : Pathology / Oncology</b>	14:00 – 15:30
FP	Steffen HEEGAARD, Rita VAN GINDERDEUREN	

14:00	4351	Histopathological vs clinical prognostic factors in conjunctival melanoma ALJAMAL RT, TUOMAALA S, KIVELÄ T–Helsinki
14:12	4352	Incidence of intra ocular lymphoma in Leuven VAN GINDERDEUREN R, VERHAMME T, VAN CALSTER J–Leuven
14:24	4353	Assessment of clonal heterogeneity in choroidal melanoma by chromosome in situ hybridization for chromosome 3 SANDINHA MT, FARQUHARSON M, ROBERTS F–Glasgow
14:36	4354	Transscleral biopsy for the determination of the chromosome 3 status in uveal melanomas AKGUEL H, ZESCHNIGK M, SCHILLING H, SCHUELER A, BORNFELD N, ANASTASSIOU G–Essen
14:48	4355	Biopsies for intraocular tumors: the Leiden experience MISSOTTEN GS, SWART W, DE KEIZER RJW, DE WOLFF-ROUENDAAL D–Leiden
15:00	4356	Teratoid medulloepithelioma: a case report and literature review HADJISTILIANOU T, DE FRANCESCO S, PIOZZI E, CAPOROSSA A, CERASE A–Siena, Milano
15:06	4357	Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva HEEGAARD S, ØSTERGAARD J, PRAUSE JU–Copenhagen

Fenix III	<b>Free papers : Immunology / Microbiology 2</b>	14:00 – 15:30
FP	Bahram BODAGHI	

14:00	4361	Inhibition of newly developing blood and lymphatic vessels after high-risk keratoplasty promotes corneal graft survival BACHMANN BO, LÜTJEN-DRECOLL E, WIEGAND S, BOCK F, STREILEIN JW, KRUSE FE, CURSIEFEN C–Erlangen, Tarrytown, Boston
14:12	4362	PI-88 inhibits infectivity and cell-to-cell spread of HSV-1 and -2 and displays antiinflammatory activity FERRO V, TRYBALA E, BERGSTRÖM T, PARISH C, FREEMAN C, CHAPMAN P–Brisbane, Göteborg, Canberra, Dublin
14:24	4363	Epidemiology of uveitis : a study of 634 patients from a single tertiary center over a period of 1 year BODAGHI B, TERRADA C, MIYARA M, CASSOUX N, WECHSLER B, LE THI HUONG D, ROZENBERG O, FARDEAU C, PIETTE JC, LEHOANG P–Paris
14:36	4364	klebsiella Endogenous Endophthalmitis- An Asian Perspective CHENG BCL, CHEE SP–Singapore
14:48	4365 <i>rf</i>	Complications of Pars Plana Vitrectomy in Acute Endophthalmitis GARCHER CREUZOT CP, LAFONTAINE PO, PASSEMARD M, ROUBEROL F, CORNUT PL, BRON AM, THURET G, ROMANET JP, CHIQUET C–Dijon, Lyon, Saint-Etienne, Grenoble
14:54	4366 <i>rf</i>	Comparative study of acute post-operative endophthalmitis with or without microbiological identification VINH V, CORNUT PL, BENITO Y, LAFONTAINE PO, THURET G, ROUBEROL F, BRON A, DENIS P, CREUZOT-GARCHER C, VANDENESCH F, ROMANET JP, CHIQUET C–Grenoble, Lyon, Dijon, Saint-Etienne

**General Assembly**16:45 – 17:30  
Fenix III**EVER General Assembly and Prize Giving****Agenda**

1. President's address
2. Minutes of the General Assembly of 2004
3. Report of the General Secretary
4. Report of the Programme Secretary
5. Report of the Treasurer, budget for 2006
6. Modification of the statutes according to the text on www.ever.be
7. Results of the elections
8. Presentation of the Board for 2005-2006
9. President Elect and Vice President Elect
10. Honorary Members
11. Report of the Scientific Sections meetings
12. Future congresses
13. Prize Giving
14. Miscellanea

Gemini I **Ocular Toxoplasmosis** 17:30 – 19:00  
 SIS Carlos PAVESIO, Uwe PLEYER

17:30	4411	Transmission – acquired X congenital and new aspects STANFORD M–London
17:45	4412	Neonatal Toxoplasmosis – long-term follow-up KODJIKIAN L–Lyon
18:00	4413	Clinical Picture – general considerations PAVESIO C–London
18:15	4414	Diagnostic Considerations PLEYER U, TORUN N–Berlin
18:30	4415	Immunology of Toxoplasmosis LIESENFELD O–Berlin
18:45	4416	New findings : possible role of Toxoplasma gondii in the development of primary intraocular lymphoma HERBORT C, PERENTES Y, CHAN CC–Lausanne, Bethesda

Gemini III **Excimer Laser Trabeculotomy (ELT) - A new, minimally invasive surgical procedure for the treatment of open-angle glaucoma** 17:30 – 19:00  
 SIS Mona PACHE, Ulrich GIERS

17:30	4421	4 years ELT in Detmold: experiences & results KLEINEBERG L–Detmold
17:45	4422	Excimer Laser Trabeculotomy (ELT) in Freiburg– two years follow up WILMSMEYER S–Freiburg
18:00	4423	Does the success rate of ELT depend on preoperative IOP? LAUTEBACH S, WILMSMEYER S, PACHE M, FUNK J–Freiburg
18:15	4424	Prospective Investigation of ELT PACHE M–Freiburg
18:30	4425	ELT & Blue blood GIERS UF, KLEINEBERG LL–Detmold
18:45	4426	Excimer Laser Trabeculotomy (ELT) - Clinical Update FUNK J–Freiburg

Pegasus **All you want know about the macular pigment** 17:30 – 19:00  
 SIS Tos TJM BERENDSCHOT, Dirk VAN NORREN



17:30	4431	Methods to measure MP VAN NORREN D, BERENDSCHOT TTJM–Utrecht, Maastricht
17:48	4432	The Relation of Macular Pigment Optical Density and Plasma Levels of Lutein and Zeaxanthin to their Dietary or Supplementary Intake – an Overview of Human Studies. SCHALCH W–Kaiseraugst
18:06	4433	MP and its relation with AMD DAVIES N–London
18:24	4434	Macular pigment: what do we know about the spatial distribution? TRIESCHMANN MB, PAULEIKHOFF D–Münster
18:42	4435	MP and its optical function(s) WEALE RA–London

Vega **Free papers : Vision Sciences** 17:30 – 19:00  
 FP Graham HOLDER, Werner SPILEERS

17:30	4441	<b>Hyperoxia-induced retinal dysfunction in rats: consequences on visual responses in the midbrain</b> CASANOVA C, ZABOURI N, HUPPE-GOURGUES F, CHEMTOB S, LACHAPPELLE P—Montreal
17:42	4442	<b>Neural-metabolic coupling in the central visual pathway</b> FREEMAN RD—Berkeley
17:54	4443	<b>Evidence for distinct ecological constraints of retinal and cortical mechanisms underlying perceptual anisotropies</b> SILVA MF, LOPES SM, GUERREIRO M, FARIA P, DUARTE L, CASTELO-BRANCO M—Coimbra
18:06	4444	<b>New methods in examination of achromatopsia</b> VARSANYI B, SAMU K, WENZEL K, FARKAS A—Budapest
18:18	4445	<b>Rod and Cone Spatial Frequency Sensitivity loss over the first seven years following retinal reattachment</b> WEIR R, SMITHSON H, BIRD A, STOCKMAN A, SHARPE TS—London
18:30	4446	<b>Comparison of intraocular stray light measurements with conventional cataract grading and contrast sensitivity estimation in elderly European drivers</b> MICHAEL R, BARRAQUER R I, EMESZ M, NISCHLER CH, HUFNAGL CH, GRABNER G, COPPENS J, VAN DEN BERG T J T P, COECKELBERGH T, WILHELM H, VAN RIJN R—Barcelona, Salzburg, Amsterdam, Antwerpen, Tübingen

Fenix I **EURETINA : Update on therapies for AMD** 17:30 – 19:00  
 Joint M. Gisbert RICHARD

17:30	4451	<b>Imaging Diagnosis - New Aspects</b> CUNHA-VAZ J, SILVA R, BERNARDES R, BAPTISTA P, FERREIRA J—Coimbra
17:42	4452	<b>Update on PDT</b> LEYS A—Leuven
17:54	4453	<b>Update on Lucentis</b> BANDELLO F—Udine
18:06	4454	<b>Mechanism of Action of Anecortave Acetate, an Angiostatic Cortisene</b> AUGUSTIN AJ—Karlsruhe
18:18	4455	<b>Update on Macugen</b> MONES J—Barcelona
18:30	4456	<b>Corticosteroids in the treatment of AMD</b> JONAS JB—Heidelberg
18:42	4457	<b>Surgery for AMD</b> RICHARD G—Hamburg

Fenix III **Free papers : Cornea 5 - Experimental and animal studies** 17:30 – 19:00  
 FP Jean-Jacques GICQUEL, Riad BEJJANI

17:30	4461	<b>Alteration of Keratan sulphate (sulphated poly-n-acetyllactoseamine repeats) in keratoconus cornea: biochemical, histochemical and ultrastructural analysis</b> AKHTAR S, KERR B, HAYES T, SALVI, SM, HAWKSWORTH NR, BRON AJ, CATERSON B, MEEK KM—Cardiff, Oxford
17:42	4462	<b>Presence of corneal neovascularization is less important factor for corneal graft survival than allo-sensitization with previous allograft</b> GUO A, KUFFOVA L, FORRESTER JV—Aberdeen
17:54	4463	<b>Comparison of Real Time Intraocular Pressure During LASIK Using Two Different Keratomes in Pig Eyes; Moria 2 vs. INTRALASE</b> HERNANDEZ VERDEJO JL, BOLIVAR G, ROMAN JM, TORRES J, TEUS MA—Madrid
18:06	4464 <i>rf</i>	<b>Immunomodulatory Role of VIP in a Murine Model of P. aeruginosa-Induced Keratitis</b> SZLITER EA, LIGHVANI S, HAZLETT LD—Detroit
18:12	4465 <i>rf</i>	<b>Corneal toxicity study of Perfluorohexyloctane in rabbit eyes</b> DIAFAS SG, LAKE S, KARAMPATAKIS VE, KARDASOPOULOS AV, STANGOS NT, MANTHOS AK—Thessaloniki
18:18	4466 <i>rf</i>	<b>Corneal Crystallin Expression in Human Repair Phenotype Keratocytes</b> MCDERMOTT AM, PEI Y, SHERRY DM—Houston
18:24	4467 <i>rf</i>	<b>Numerical simulation of corneal transport processes</b> TIGHE B, LI LY—Birmingham
18:30	4468 <i>rf</i>	<b>Cellular activity in human re-grafts 1 – 30 years primary surgery</b> GAN L, FAGERHOLM P, STENEVI U—Linköping, Göteborg
18:36	4469 <i>rf</i>	<b>Evaluation of Megacell MEM as a corneal storage medium</b> SMITH VA—Bristol

**Social Activity**

20:00 – 22:00  
 Marinotel garden

**EVER Farewell Dinner**

## RETINA / VITREOUS

- 401 Visual function and subjective perception of visual ability following vitrectomy and epiretinal membrane peel surgery  
GHAZI-NOURI SM, TRANOS PG, RUBIN GS, ADAMS ZC, CHARTERIS DG—London
- 402 Sub-Tenon's anaesthesia for vitreoretinal surgery in patients receiving oral anticoagulation  
ELLIES P, BEJJANI R, ELLIES E—Toulouse, Paris
- 403 Intraretinal proliferative vitreoretinopathy. Immunohistochemical study of peripheral retinectomies  
PASTOR JC, DE LA FUENTE MA, MENDEZ MC, SANABRIA RM, GARCÍA-ARUMÍ J—Valladolid, Barcelona
- 404 Intraocular immunopathology following silicone oil tamponade  
WICKHAM LJ, ASARIA RHY, LUTHERT PJ, CHARTERIS DG—London
- 405 Perfluorocarbonate liquid as a temporary tamponade for complicated inferior retinal detachments  
KUFFOVA L, BIESTER S, FORRESTER JV—Aberdeen
- 406 The relevance of the adhesive properties of leukocytes in the Diabetic Retinopathy  
SERRA AM, WADDELL JM, COTTER MA, DUNCAN L, FORRESTER JV—Aberdeen
- 407 Inducible nitric oxide synthase is involved in increased leukocyte adhesion to retinal vessels induced by diabetes  
LEAL EC, MANIVANNAN A, COTTER M, AMBROSIO AF, FORRESTER JV—Coimbra, Aberdeen
- 408 Intravitreal triamcinolone acetonide as an adjuvant therapy to panretinal photocoagulation for proliferative retinopathy with high risk characteristics in type 1 diabetes: case report with 1 year and 4 months follow-up  
KYTÖ JP, KROOTILA K, LUMISTE E, HIETALA K, PALOHEIMO M, SUMMANEN PA—Helsinki
- 409 Foveal neovascularization in diabetic retinopathy  
SUMMANEN PA, TOMMILA P, LUMISTE E—Helsinki
- 410 Antiphospholipid antibodies and retinal thrombosis  
MANGANELLI C, TURCO S, BALESTRAZZI E—Roma
- 411 Isolating triamcinolone acetonide particles for intravitreal use with different pore size filters  
RIGAL SASTOURNE J-C, MULLOT H, PAYEN C, GENTES P, BORNE-PONS M, RENARD JP, MAURIN JF—Paris, Saint-Mandé
- 412 Wild-type and Sorsby's fundus dystrophy mutant TIMP-3 exhibit differential thermal stability  
MAJID MA, SMITH VA, BAKER AH, NEWBY AC, DICK AD—Bristol
- 413 Retinal degeneration is delayed by eye pigmentation and heterozygosity in the P23H rat  
CUENCA N, PINILLA I, SAUVÉ Y, MARTÍNEZ-NAVARRETE G, LUND RD—Alicante, Zaragoza, Utah
- 414 Cell-based therapy preserves photoreceptor connectivity in a model of retinal degeneration  
PINILLA I, SAUVÉ Y, CUENCA N, LUND RD—Zaragoza, Edmonton, Alicante, Salt Lake City
- 415 Anatomical and functional differences between RCS rat and P23H retinal degeneration  
PINILLA I, CUENCA N, SAUVÉ Y, LUND RD—Zaragoza, Alicante, Edmonton, Salt Lake City
- 416 Intervention to reduce inappropriate fluorescein angiography requests  
RAJAK SN, CURRIE ADM, CASSWELL AG, ECKSTEIN MB—Brighton
- 417 Transpupillary thermotherapy (TTT) in Retinal Angiomatous Proliferation (RAP)  
PELOSINI L, MCHUGH DA—London
- 418 Diffuse Laser for Drusen reduction in High risk age related maculopathy  
ADEWOYIN T A, SIVAGNANAVEL V, CHONG NHV—London
- 419 Photodynamic therapy in combination with intravitreal triamcinolone for myopic CNV  
DEGENERING RF, JONAS JB—Heidelberg
- 420 Plasma complement C3adesArg is raised in neovascular age-related macular degeneration  
SIVAPRASAD S, BAILEY TA, CHONG NHV—London, Bedfordshire
- 421 Effect of timolol maleate on subfoveal choroidal blood flow measured by laser Doppler flowmetry  
LINGUERRI S, PARMEGGIANI AL, FALSIN B, RIVA CE—Bologna, Roma
- 422 Combined photodynamic therapy and intravitreal triamcinolone acetonide for neovascular age-related macular degeneration associated with pigment epithelial detachment  
ELLIES P, BEJJANI R—Toulouse, Paris
- 423 Hsp90 inhibitor modulates ubiquitin–proteasome pathway linked protein aggregation in human ARPE–19 cells  
RYHÄNEN T, KAARNIRANTA K, KUUSISTO E, MIETTINEN R, SALMINEN A, TERÄSVIRTA M, UUSITALO H—Kuopio
- 424 The Effect of Posterior Juxtasclear Triamcinolone Acetonide on Choroidal Neovascular Growth After Photodynamic Therapy With Verteporfin For Age-Related Macular Degeneration  
VAN DE MOERE ASJ, TALKS SJ, SANDHU SS—Newcastle upon Tyne
- 425 Photodynamic therapy for subfoveal choroidal neovascularization. A colour doppler study  
CELLINI M, PAZZAGLIA A, ZAMPARINI E, CAMPOS EC—Bologna
- 426 Retinal Vessel Diameter in Asymmetric Age-related Macular Degeneration  
SANDHU R, SIVAPRASAD S, MADILL S, CHONG V—London
- 427 Optical coherence tomography findings following combined PDT with verteporfin and intravitreal triamcinolone acetonide in exudative AMD  
TEUS MA, FIGUEROA M, GÓMEZ MI, ORTEGA M—Madrid
- 428 A pilot study investigating the safety and efficacy of a novel photodynamic agent, LS11  
HUSSAIN B, LIEW SHM, HAMILTON AMP, MARSHALL J—London
- 429 Age-related macular degeneration in African patients from D R Congo  
KAIMBO WA, KAIMBO D, MISSOTTEN L—Kinshasa, Leuven
- 430 Optical Coherence Tomography Findings in Welding Arc Maculopathy  
LUCAS RS, HARPER CA, MCCOMBE MF, ZAMIR E—Melbourne
- 431 Optical Coherent Tomography and Retinitis Pigmentosa -Therapeutic approach  
GONZALVEZ BG, HERA HR, SARMENTO SA, MOUILLON MM—Grenoble
- 432 Central retinal thickness and volume after uncomplicated cataract surgery  
DEGENERING RF, VEY S, KAMPPETER B, BUDDÉ W, SAUDER G, JONAS JB—Mannheim
- 433 A peek at the OCT front intensity peak  
KESTING S, VECKENEER M, MISSOTTEN T—Rotterdam
- 434 Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency in retinal vein occlusions  
PINNA A, CARRU C, SOLINAS G, DONAERA M, ZINELLU A, CARTA F—07100 Sassari, Italy
- 435 Space-filling properties of retinal vessels and axial length  
PATTON N, MACGILLIVRAY T, DHILLON B—Princess Alexandra Eye Pavilion, Edinburgh
- 436 Central retinal artery occlusion with simultaneous contralateral central retinal vein occlusion  
CHRONI FC, SKINNER KC, GREGORY PT, MERRICK CD, LAPPAS I—St. Leonards-on-Sea, Athens
- 437 Roth's spots and BRAO simultaneously in same patient  
SKINNER KC, CHRONI FC, MERRICK CD—St-Leonards-on-Sea
- 438 Quinine: intoxication or vascular spasm?  
NEUDECK M, KLOPPER M, LANZL I—Munich
- 439 An illuminated scleral indenter in the teaching of indentation techniques to trainee ophthalmologists  
DWARIKA D, BHOLA RM, SCOTT RAH—Birmingham, Sheffield
- 440 The ERG assessment of rabbit retina vulnerability to intravitreal triamcinolone  
ZUEVA M, TSAPENKO I, NEROEV V, TANKOVSKY V, MASLOVA-KHOROSHILOVA I, MIZEROVA O—Moscow
- 441 Correlation between stage of retinopathy of prematurity and optic disc morphology  
OBERACHER-VELTEN I, ELFLIN H, LORENZ B—Regensburg
- 442 Ischemic Retinopathy with stem cell auto graft?  
RAVINDRANATHAN R, TAHHAN M—West Bromwich

- 443 **Microperimetry Evaluation in Serpiginous Choroidopathy**  
PLAZAS A, RUIZ-LAPUENTE C J, DEL ESTAD A, RUEDA T–Sevilla
- 444 **Effects of patent blue on human retinal function**  
LÜKE C, LÜKE M, SICKEL W, SCHNEIDER T, MARZELLA G, KIRCHHOFF B–Cologne, Tübingen
- 445 **Multispectral Fundus Analysis**  
*rf* CALCAGNI A, STYLES IB, CLARIDGE E, ORIHUELA-ESPINA F, GIBSON JM–Birmingham
- 446 **Zinc in Drusen**  
*rf* PETO T, LENGVEL I, FREDERICKSON C, VAN KUIJK E–London, Galveston
- 447 **Morphological Features of Classic and Occult subfoveal Choroidal Neovascular Membrane using OCT -An aid to diagnosis**  
ADEWOYIN TA, KHAN J, CHONG NHV–London
- 448 **Photodynamic therapy versus surgical removal from choroidal neovascularisation in high myopia**  
*rf* HERA R, VINH MOREAU V, GONZALVEZ B, MILLET JY, ROMANET JP, MOUILLON M–Grenoble
- 449 **Audit of diabetic referrals – Rationalising patient referrals via a three-tier system**  
*rf* FLETCHER EC, ADEWOYIN T, CHONG NHV–London
- 450 **Detection of associated ocular lesions during screening of diabetic retinopathy**  
*rf* DEB-JOARDAR N, THURET G, GERMAIN N, GARCIN AF, MANOLI P, GAVET Y, ESTOUR B, GAIN P–Saint-Etienne
- 451 **A two-year prospective study of mild nonproliferative retinopathy in subjects with diabetes type 2 undergoing intensive oral triotherapy. Progression of retinopathy under stabilized metabolic control**  
*rf* DUARTE L, RIBEIRO ML, NUNES S, LOBO C, BERNARDES R, GERALDES E, FARIA DE ABREU JR, CUNHA-VAZ JG–Coimbra
- 452 **Subtenon triamcinolone acetonide to treat diabetic macular edema**  
*rf* CELLINI M, ZAMPARINI E, BRAVETTI GO, BELLUSCI C, CAMPOS EC–Bologna

**VISION SCIENCES / ELECTROPHYSIOL. / PHYSIOL. OPTIC**

- 453 **Comparison of measurements with OCT2 and OCT3 in patients with achromatopsia**  
VARSANYI B, SOMFAI GM, LESCH B, FARKAS A–Budapest
- 454 **Preventive effect of pigmentation on ERG responsiveness in P23H rats**  
SAUVÉ Y, PINILLA I, CUENCA N, LUND RD–Edmonton, Zaragoza, Alicante, Salt Lake City
- 455 **Quantitative Phenotyping of Stargardt Disease with Novel Psychophysical Perimetric Techniques and Multifocal Electrophysiology**  
MAIA-LOPES S, SILVA M F, FARIA P, SILVA E, REIS A, CASTELO-BRANCO M–Coimbra
- 456 **Distinct response topographies observed with SLO-based and conventional multifocal ERG**  
SEBASTIÃO A, MAIA-LOPES S, NUNES S, REIS A, CASTELO-BRANCO M–Coimbra
- 457 **Visual Information Processing from extracellular recording in Lateral Geniculate Nucleus (LGN) of the rat**  
CEPEDA IR, CASTELLANOS N, PANETSOS F, SANCHEZ-RAMOS C–Madrid
- 458 **Effect of a polarized on photopic contrast sensitivity and disability glare**  
DEL MORAL MARTÍNEZ MI, SANCHEZ-RAMOS C, PUELL MC, PEREZ-CARRASCO MJ, LANGA A–Madrid
- 459 **Monochromatic Ocular Aberrations in Professional Tennis Players**  
GICQUEL JJ, NGUYEN-KHOA JL, CHÂTEAU N, DIGHIRO PL–Poitiers, Paris, Orsay
- 460 **Refractive error changes in young adults during a period of 3 years**  
JORGE J, QUEIROS A, ALMEIDA JB, PARAFITA MA–Braga, Santiago de Compostela
- 461 **The impact of long myopic defocus on eye growth and refractogenesis in children with hyperopia**  
TARUTTA EP–Moscow
- 462 **Effect of lasik on pupil size and accommodation in myopic patients**  
GIL R, HERNÁNDEZ-VERDEJO JL, RAMZY M, TEUS MA, FUENTES I–Madrid, Alicante
- 463 **Accommodative response after ICL implantation in myopic eyes**  
SHELUDCHENKO NV, AVETISOV SE, SHELUDCHENKO VM–Moscow

- 464 **A randomised cross-over trial to assess vision-related quality of life with an autofocus biopic telescope**  
HARPER RA, CHANDLER C, REEVES BC, SZNAPKA J, DICKINSON CM–Manchester, Bristol
- 465 **Variation of visual symptoms in terms of type and degree of ametropia**  
VIDAL LÓPEZ J, SOBRADO CALVO P–Murcia
- 466 **Associations between specific measures of vision and Vision-Related Quality of Life in patients with Bothnia Dystrophy, a defined type of Retinitis Pigmentosa**  
BURSTEDT MSI, MÖNESTAM E, SANDGREN O–Umeå
- 467 **Tinted contact lenses in Bothnia dystrophy**  
JONSSON ÅC, SANDGREN O, BURSTEDT MSI–Umeå
- 468 **Electrophysiological Changes of Retinal Ganglion Cells in RCS Rats during Retinal Degeneration**  
YIN ZQ, CHEN ZS, CHEN S, WANG SJ–Chongqing, Nanchang

**IMMUNOLOGY / MICROBIOLOGY**

- 469 **Cross – Infection and Contact Ophthalmic Devices: Clinical Trials of a Disposable Ophthalmic Barrier System**  
FRANKLIN V, HENLEY C, TIGHE B, KERR J, GEE H, FLANAGAN J–Birmingham, Croydon, Ramsbury
- 470 **Adhesion properties of ocular isolates of Staphylococcus epidermidis**  
PINNA A, SECHI LA, ZANETTI S, USAI D, DESSOLE L, CARTA F–Sassari
- 471 **Serum Prolactin Levels in HLA B27-Associated Uveitis**  
PROENCA H, LOPES D, FERREIRA C, MIRANDA M, CASTANHEIRA-DINIS A, MONTEIRO GRILLO M–Lisbon
- 472 **Immunofluorescence against immunohistochemistry in the diagnosis of ocular conjunctival immune diseases**  
FERNANDEZ ALONSO N, MENDEZ MC, PIGAZO JM, SAORNIL MA, HERRERAS JM, CALONGE M–Valladolid
- 473 **Rhinocerebral Mucormycosis**  
PLAZAS A, RUIZ LAPUENTE CJ, DEL ESTAD A–Sevilla
- 474 **Bacterial identification using PCR in acute endophthalmitis**  
CHIQUET C, LAFONTAINE PO, VINH V, THURET G, BENITO Y, CREUZOT-GARCHER C, ROUBEROL F, PALOMBI K, DENIS P, BRON A, ROMANET J-P, VANDENESCH F–Grenoble, Dijon, Saint-Etienne, Lyon
- 475 **Intravitreal Moxifloxacin monotherapy of endophthalmitis in an experimental model**  
MONTERO-MORENO JA, FERRER C, RODRIGUEZ AE, FERNANDEZ J, ABAD JL, ALIO JL–Alicante
- 476 **Serum Prolactin Levels and Behçet Disease**  
*rf* PROENCA H, GONÇALVES C, FERREIRA C, MIRANDA M, CASTANHEIRA-DINIS A, MONTEIRO GRILLO M–Lisbon
- 477 **Contribution of lumbar puncture and CSF analysis in the diagnosis of Vogt-Koyanagi-Harada disease**  
*rf* BOUCHENAKI N, HERBERT CP–Geneva, Lausanne
- 478 **Complications of Pars Plana Vitrectomy in Acute Endophthalmitis**  
*rf* GARCHER CREUZOT CP, LAFONTAINE PO, PASSEMAR M, ROUBEROL F, CORNUT PL, BRON AM, THURET G, ROMANET JP, CHIQUET C–Dijon, Lyon, Saint-Etienne, Grenoble
- 479 **Comparative study of acute post-operative endophthalmitis with or without microbiological identification**  
*rf* VINH V, CORNUT PL, BENITO Y, LAFONTAINE PO, THURET G, ROUBEROL F, BRON A, DENIS P, CREUZOT-GARCHER C, VANDENESCH F, ROMANET JP, CHIQUET C–Grenoble, Lyon, Dijon, Saint-Etienne

**Keynote Lectures**

BAILEY, I: Friday, 15:45  
 BARRAQUER, J: Wednesday, 17:15  
 BEEBE, D: Friday, 10:15  
 FORRESTER, J: Thursday, 15:45  
 KAUFMAN, P: Saturday, 10:15  
 KINOSHITA, S: Thursday, 10:15  
 SÖDERBERG, P: Wednesday, 18:00

- ABRAHAM E: 3365, 4313  
 ABU EL ASRAR A: 1341, 1345, 2251, 2254, 3431  
 ACAR Z: 2244  
 ADAMIS T: 2214, 3233  
 ADEWOYIN T: 418, 447, 4236  
 AGOSTINI HT: 3231  
 AHAD M: 4262  
 AINSWORTH G: 4112  
 AKGUEL H: 3341, 4354  
 AKHTAR S: 249, 4461  
 AL FAKIH A: 230, 2429  
 ALIAS EG: 310  
 ALI RR: 2212, 2355  
 ALJAMAL R: 4351  
 ALLEMANN R: 2131, 3333  
 ALLENDE A: 252  
 AMER R: 205  
 ARIF F: 204, 3347  
 ARRANZ E: 213, 3353  
 ASLAM T: 358, 3451  
 ATHERTON S: 4161  
 AUGSBURGER JJ: 4151  
 AUGUSTIN A: 4454  
 AUTRATA R: 222, 223  
 AYALA M: 3265  
 BACHMANN B: 4361  
 BAILEY I: 3411, 3412, 3413, 3414, 3415  
 BALASUBRAMANIAM B: 2363  
 BALEANU D: 2235  
 BANDELLO F: 3133, 4453  
 BAPTISTA P: 4141  
 BARBER C: 1323  
 BARBUR J: 4343  
 BARRANDON Y: 2226  
 BARRAQUER RI: 3124  
 BARTON K: 4212  
 BATES D: 2211  
 BAYLIS O: 350, 3455  
 BEHNDIG A: 2421  
 BEHRENS A: 224, 225, 2222, 2424  
 BENITEZ-DEL-CASTILLO J: 2322  
 BERENDSCHOT TT: 2311  
 BERNARDES R: 2315, 2316  
 BHAT SP: 3364  
 BIALLOSTERSKI C: 334  
 BLAISE P: 2242  
 BLANCO-MEZQUITA T: 234, 3257  
 BOCCARA AC: 2442  
 BODAGHI B: 1346, 2155, 2451, 2457, 4363  
 BOGDANICI C: 4266  
 BORQUE E: 312  
 BORRUAT FX: 2432  
 BOSCHI A: 2431  
 BOUCHENAKI N: 477, 4267
- BOUFFIOUX C: 258, 2343  
 BOULTON M: 2145  
 BOURGES JL: 2423  
 BOURGHARDT PEEBO B: 232, 3156  
 BOYCHUK I: 273  
 BRAUTASET R: 271  
 BRAVETTI GO: 344  
 BRINKMANN R: 4146  
 BRON AM: 2334, 3223  
 BRON AJ: 2461  
 BRUENECH R: 2164  
 BRUST K: 288  
 BUNIATYAN I: 327  
 BURD H: 4322  
 BURNIER MN: 4252  
 BURSTEDT M: 466  
 CALCAGNI A: 445, 4136  
 CALLEJO S: 3243  
 CARASSA RG: 3422  
 CARLSSON E: 2465  
 CARNOVALE SCALZO G: 286, 330  
 CARTER J: 2113  
 CASANOVA C: 4441  
 CELLINI M: 425, 452, 4338  
 CEPEDA I: 457  
 CHANG M: 3252  
 CHAPMAN P: 3436  
 CHENG BCL: 4364  
 CHIAM P: 292, 345  
 CHIQUET C: 474  
 CHRONI FC: 436  
 CHUNG S: 3361  
 CIMINO L: 2153  
 CLAERHOUT I: 2125  
 COLBY K: 4116  
 COUPLAND S: 4155, 4253  
 CROSS V: 320  
 CUENCA N: 262, 413, 2366  
 CUNHA-VAZ J: 2411, 4451  
 CVEKL A: 4312  
 DA COSTA SA: 318  
 DALKE C: 2117, 3165  
 DAMATO B: 4154  
 DARTT DA: 2321  
 DAVIES J: 2453  
 DAVIES N: 4433  
 DAVIES V: 2364  
 DAYANIR V: 4121  
 DEB-JOARDAR N: 370, 450, 4336  
 DECAUDIN D: 4256  
 DECOCK C: 2243  
 DE FRUTOS-BARAJA JM: 374, 3146  
 DEGENRING RF: 419, 432  
 DE GREEF S: 2341  
 DE KEYZER K: 3458  
 DELAMERE N: 2135  
 DEL MORAL MARTÍNEZ I: 458  
 DENIS P: 3425  
 DESJARDINS L: 3142  
 DE SMET MD: 1344, 2156, 2256, 2354, 2413, 3234  
 DE SOUZA RAMALHO P: 2332, 2333  
 DEUTER C: 2353  
 DIAFAS S: 242, 4465  
 DICK AD: 2255, 2351
- DIGHIERO PL: 2221  
 DIXON R: 3346  
 DOELEMAYER A: 3222  
 DOSSO A: 3232  
 DREXLER W: 2313  
 DUA HS: 2224  
 DUARTE L: 451, 4337  
 DUBOIS V: 343  
 DWARIKA D: 364, 439, 3115  
 EHLKEN C: 2336  
 EIBL K: 2136  
 ELLIES P: 402, 422  
 EPERON S: 279  
 FAGERHOLM P: 2111  
 FERNANDES P: 210, 316  
 FERNANDEZ ALONSO N: 472  
 FERNANDEZ EJ: 2446  
 FERREIRA J: 4145  
 FERRERAS A: 306, 307  
 FERRO V: 3434, 4362  
 FLETCHER E: 449, 4231, 4335  
 FRANKLIN V: 240, 469, 3359  
 FRANKS W: 323, 3424  
 FREEMAN R: 4442  
 FUCHSJÄGER-MAYRL G: 2133  
 FUNK J: 4426  
 GALAND A: 3125  
 GAMBRELLE J: 3147  
 GAN L: 245, 4468  
 GARCHER CREUZOT C: 478, 3227, 4365  
 GARCIA ABELLAN V: 305  
 GARCIA-FEIJOO J: 3423  
 GARHOFER G: 2233  
 GHAZI-NOURI SM: 401  
 GICQUEL JJ: 212, 459, 2225  
 GIERS U: 4425  
 GIL-CAZORLA R: 462, 3352  
 GIRAO H: 4315  
 GLASSER A: 3461, 3465  
 GOMBOSS K: 3454  
 GONZALEZ-MEIJOME JM: 218, 219  
 GONZALVEZ B: 431  
 GRANGE JD: 3246  
 GRAW J: 4311  
 GRIFFITH M: 4215  
 GRUS F: 237, 3356  
 GUEUDRY J: 365, 3116, 3254  
 GUGLETA K: 4221  
 GUO A: 4462  
 GUO X: 363, 2115  
 GUTIERREZ C: 324, 335  
 HADJISTILIANOU T: 3343, 4356  
 HARDARSON S: 2231  
 HARPER R: 464  
 HARRIS A: 4223  
 HAUGEN IB: 2163  
 HAWLINA M: 4243, 4341  
 HEEGAARD S: 4357  
 HEGDE K: 3264, 3362  
 HERA R: 448, 4237  
 HERBORT CP: 1342, 1343, 2151, 2152, 2253, 2456, 4416  
 HERNANDEZ VERDEJO JL: 201, 4463  
 HICKS C: 4211  
 HO A: 2443
- HOLDER G: 1321, 1324, 4246, 4344  
 HOLMES JM: 2262  
 HUHTALA A: 250  
 HUNTBACK J: 3255  
 HUSSAIN B: 428  
 IDREES F: 3321  
 IOMDINA EN: 4325  
 JAGER MJ: 3241  
 JENSEN PK: 4152  
 JIRSOVA K: 229, 2428  
 JONAS JB: 3114, 3132, 3135, 4233, 4456  
 JONES S: 3324  
 JONSSON : 467  
 JORGE J: 460, 2261  
 JOUSSEN A: 3131  
 KAARNIRANTA K: 248, 2143  
 KAIMBO WA KAIMBO D: 429  
 KAMPETER B: 274, 314  
 KARACORLU M: 3134  
 KARAMPATAKIS V: 208, 293  
 KARLSSON JO: 4314  
 KAUFMAN PL: 4163  
 KAWASAKI A: 2434, 2435  
 KEATING D: 4242  
 KESTELYN P: 2121  
 KESTING S: 433  
 KHAIRALLAH M: 2154  
 KHAN B: 4115  
 KHAN-LIM D: 287  
 KINOSHITA S: 2223  
 KLEINEBERG L: 4421  
 KNOP E: 2462  
 KOCH P: 4135  
 KODJIKIAN L: 3342, 4412  
 KOENIG K: 2441  
 KÖHN L: 354  
 KONSTAS AGP: 3421  
 KOROBELNIK JF: 2414  
 KOSHITZ IN: 4326  
 KOTLIAR K: 2234, 4321  
 KOULIKOVSKA M: 217  
 KRUSE F: 2325  
 KUBE T: 4122  
 KUFFOVA L: 405  
 KULJACA Z: 346, 367, 3118  
 KUPPERMAN L: 3136  
 KYTÖ J: 408  
 LACHAPPELLE P: 4244  
 LAEMMER R: 302  
 LAKE S: 289  
 LALIENA SANTAMARÍA JL: 301  
 LAM B: 4241  
 LANDIS T: 3313  
 LANGE C: 3435  
 LANGZ I: 2266  
 LAUTEBACH S: 4423  
 LAZUK AV: 260  
 LEAL E: 407  
 LEE HK: 2463  
 LEE S: 4235  
 LEROY B: 1322, 4245, 4342  
 LEYS A: 2415, 4452  
 LIBONDI T: 349, 3453  
 LIEKFELD A: 3126  
 LIENART M: 2344

- LIESENFELD O: 4415  
LIINAMAA J: 2331  
LINGUERRI S: 421  
LIRA M: 215, 216  
LIU C: 4111  
LOCKWOOD A: 333, 3328  
LOPEZ-GIL N: 3464  
LOPEZ PEÑA MJ: 311  
LUBATSCHOWSKI H: 2444  
LUCAS R: 430  
LÜKE C: 444  
LY L: 3143  
MACHOWICZ-MATEJKO E: 368  
MADIGAN M: 3245  
MAHOMED A: 238, 239, 3357, 3358  
MAIA-LOPES S: 455  
MAIER M: 4323  
MAJID M: 412  
MANGANELLI C: 410  
MANN A: 231, 235, 3155, 3354  
MARTÍNEZ-GARCÍA A: 317, 340, 3323  
MARTINEZ-NAVARRETE GC: 263, 2367  
MARTIN G: 4134  
MATIAS I: 284  
MAYORAL F: 309  
McDERMOTT A: 243, 4466  
McNICOL LA: 4162  
MEEK K: 2422  
MELLERIO J: 4131  
MELTENDORF C: 233, 3256  
MENDEZ MC: 3345  
MENKE M: 4143  
MENNECIER G: 353  
MERGLER S: 265, 2467  
MERJAVÁ S: 206  
MESSMER EM: 3153  
MICHAEL R: 228, 2427, 4446  
MICHELS S: 2213  
MIDENA E: 4153  
MILANO G: 304  
MILEA D: 2433  
MISIUK HOJLO M: 371  
MISSOTTEN G: 372, 4355  
MONES J: 4455  
MONTERO-MORENO JA: 475, 4234  
MOORE J: 4214  
MORILLA A: 376  
MOURIAUX F: 373  
MUIÑOS DÍAZ Y: 3247  
MULAK M: 3111  
MÜLLER L: 2323  
MUNOZ MORALES A: 281  
MURAINÉ M: 2126, 2227  
NAGARAJ R: 3266  
NASCIMENTO SM: 2314  
NESTEL A: 276, 339, 3322  
NEUDECK M: 438  
NEVES C: 4222  
NIELSEN K: 362, 2112  
NILSSON M: 291  
NUBILE M: 3251  
NUNES S: 4144  
OBERACHER-VELTEN I: 337, 441, 3224  
OBROSOVA I: 2335  
OEHRENS A: 2265  
PACHE M: 4123, 4424  
PARDIÑAS BARON N: 308  
PASTOR JC: 403, 3433  
PATTON N: 435  
PAVESIO C: 4413  
PE'ER J: 3244  
PEDROSA DOMELLOF F: 2161  
PEETERS L: 2342  
PELOSINI L: 351, 417, 3456  
PELS E: 2122  
PEREIRA P: 294  
PESCE G: 209, 331  
PETO T: 446, 1347, 4137, 4331  
PETRASH M: 3363  
PETROPOULOS I: 3334  
PHERWANI A: 328  
PICCIRILLO V: 236, 3355  
PICHLER A: 336  
PIEH C: 2162  
PINILLA I: 414, 415  
PINNA A: 434, 470  
PLANT G: 3311  
PLAZAS A: 443, 473  
PLEYER U: 2455, 4414  
POLSKA E: 2232  
POURNARAS C: 3235, 3331  
POURNARAS JAC: 341, 3326  
PRAUSE JU: 4255  
PRIMAVERA V: 3141  
PROENCA H: 471, 476, 4263  
PRZYDRYGA J: 290, 3152  
PUEYO V: 313  
PUK O: 356, 3163  
QUEIROS A: 357, 359  
RAJAK S: 416  
RAMIREZ AI: 257  
RANINEN A: 277, 2267  
RANTALA J: 256  
RASUL N: 214  
RAVINDRANATHAN R: 360, 442  
RECHTMAN E: 4225  
REITSAMER H: 3164  
REMKY A: 338, 3226  
RENARD E: 275  
RESSINIOTIS T: 267, 355  
RICHARD G: 4457  
RIECK P: 2228  
RIGAL SASTOURNE JC: 411  
RIVA C: 3332  
ROCHA DE SOUSA A: 264, 2466  
ROLDAN-PALLARES M: 3432  
ROMANOWSKA DIXON B: 3145, 3344  
RÖNKKÖ S: 280  
ROSEN R: 2312  
ROSNER M: 342  
RYABTSEVA AA: 4324  
RYHÄNEN T: 423  
SAFRAN A: 3312  
SALAZAR JJ: 319  
SANDGREN O: 3112  
SANDHU R: 426  
SANDINHA T: 4353  
SANTOS L: 220, 221  
SAORNIL ALVAREZ MA: 3144, 4251  
SAUVÉ Y: 454  
SAVY O: 283  
SAW SM: 3113, 3211, 3212, 3213  
SCHAEFFEL F: 3161, 3462  
SCHALCH W: 4432  
SCHMETTERER L: 3336  
SCHMIDT S: 4265  
SEBASTIÃO AR: 456  
SERRA A: 406  
SHAH P: 329, 3327  
SHAMS P: 348, 2114, 3452  
SHELUDCHENKO V: 463  
SII F: 278, 332  
SILVA M: 4443  
SILVA R: 2412  
SIVAPRASAD S: 420, 4132  
SJÖSTRAND J: 272  
SKINNER K: 366, 437, 3117  
SMITH J: 2352  
SMITH V: 226, 246, 2425, 4469  
SOBRADO-CALVO P: 268, 270  
SÖDERBERG P: 3261  
SOHNGEN P: 2241  
SPIRE M: 2263  
SRIVASTAVA O: 3263  
STALMANS I: 3221  
STANFORD M: 4411  
STEFANSSON E: 3335, 4224  
STRAUSS RW: 4142  
STRUBLE C: 2132  
SUMMANEN P: 409, 4333  
SUZUKI JUNIOR ER: 322  
SZLITER E: 241, 4464  
TANDON R: 4113, 4114  
TARUTTA E: 461  
TASSIGNON MJ: 3123  
TATAR O: 261, 2365, 4232  
TERMAN A: 2142  
TERRADA C: 2252  
TESSEM MB: 347  
TETZ MR: 3122  
TEUS M: 427, 3351  
THEN KY: 4213  
THOMAS V: 4264  
THURET G: 227, 2124, 2426  
TIFFANY J: 3151  
TIGHE B: 202, 244, 4216, 4467  
TOIVONEN P: 3242  
TONINI M: 315  
TÓTH M: 303  
TREVITHICK JR: 3262  
TRIARIDIS S: 247  
TRIESCHMANN M: 4434  
TUGAL-TUTKUN I: 2452, 2454  
TUISKU I: 2324, 3154  
URTTI A: 2144  
UUSITALO H: 2141  
VALAMANESH F: 285  
VA'MOS R: 361  
VAN DE MOERE A: 424  
VAN DER VALK P: 4254  
VAN DER WERF F: 2264  
VAN DE VEIRE S: 325  
VAN GINDERDEUREN R: 4352  
VAN NORREN D: 4431  
VARSANYI B: 453, 4444  
VERBRAAK F: 4332  
VERONESE RODRIGUES ML: 2464  
VIDAL LÓPEZ J: 269, 465  
VIDAL-SANZ M: 253, 326  
VIDE ESCADA EICKMANN A: 375  
VILLAFRUELA I: 251  
VILLEGAS PEREZ MP: 254, 255  
VINH V: 479, 4366  
VITOVA A: 207  
VOROS G: 266, 352, 3457  
VOSSMERBAEUMER U: 203, 2361  
VOTRUBA M: 2116, 3162  
VRENSSEN GFJM: 3121  
VULSTEKE C: 3225  
WEALE RA: 321, 4435  
WEIGERT G: 2134  
WEIR R: 4445  
WELGE-LÜSSEN UC: 4133  
WICKHAM L: 404  
WILLERMAIN F: 4261  
WILLIAMS M: 211  
WILMSMEYER S: 4422  
WIMMERS S: 282  
WOJTKOWSKI M: 2445  
WOLFFSOHN J: 3463  
WOOD T: 3253  
WRIDE N: 369  
YILMAZ G: 4334  
YIN Z: 468  
YU A: 259, 2362  
ZANETTI E: 2123  
ZEYEN T: 3325  
ZUEVA MV: 440

EVER gratefully acknowledges the sponsoring by the following companies:

**MAIN Sponsor**



**MAJOR Sponsor**



**SIS Sponsors**



ALLERGAN

DSM



HEIDELBERG  
ENGINEERING



Santen



**Exhibitors**



HEIDELBERG  
ENGINEERING



LIDEL



**About the programme book**

This programme book is organised chronologically. The sessions are colour-coded:

Special Interest Symposium (SIS)

Keynote Lecture

Workshop

Free Papers

General Assembly

Poster Session

Joint Meeting

Course

Social Activity


FP = Free Paper session

SIS= Special Interest Symposium

rf = Rapid Fire presentation

FRO = Funds for Research in Ophthalmology

Three digit numbers refer to posters, four digit numbers refer to oral presentations.



# VISIONARY

## **A vision for innovation...**

- Committed to the development of groundbreaking new medicines for key unmet needs
  - Glaucoma
  - Macular degeneration
  - Diabetic retinopathy

## **A vision for worldwide health...**

- A founding partner in the *International Trachoma Initiative*, created to help treat the world's leading cause of preventable blindness

## **A vision for tomorrow...**

- Advancing treatment by supporting healthcare professionals and patients



EVER 2005	Gemini I	Gemini III	Pegasus	Vega	Fenix I	Fenix III
<b>Wednesday 5 October 2005</b>	<b>COURSE I</b> Electrophysiology G HOLDER, B LEROY, C BARBER	<b>COURSE II</b> Appropriate use of ancillary and new imaging methods in the appraisal of intraocular inflammatory diseases — A ABU EL ASRAR, B BODAGHI, CP HERBERT, MD DE SMET				
14:00 - 17:00	Welcome by the President EVER 2005 Nick GALLOWAY					in Fenix III
17:00 - 17:15	AER Lecture : Evolution of Cataract Surgery, Corneal Transplantation and Refractive Surgery — Joaquim BARRAQUER					in Fenix III
17:15 - 18:00	EVER Lecture : A little bit of light on the lens — Per SÖDERBERG					in Fenix III
18:00 - 18:45	EVER Welcome Garden Party					in Marimotel
<b>Thursday 6 October 2005</b>						
08:30 - 10:00	FP: Molecular Biology / Genetics / Epidemiology 1 J GRAW, M VOTRUBA	Eye Banking J CLAERHOUT	FP: Physiology / Biochemistry / Pharmacology 1 N DELAMERE	Retinal pigment epithelium H UUSTALO	Emerging agents and novel aspects in inflammatory eye diseases — L CIMINO, CP HERBERT	Extraocular muscles, new observ. and clin. implicat. R BRUNECH, F FREDROSA, A SAFRAN
10:15 - 10:55	Keynote Lecture : Ocular surface regeneration: Present and Future — Shigeru KINOSHITA					in Fenix III
11:00 - 12:30	VEGF – from gene to therapy A CHURCHILL	Corneal Wound Healing J GICQUEL, PL DIGHERO	FP: Physiology / Biochemistry / Pharmacology 2 E STEFANSSON, L SCHMETTERER	FRO 1 MJ TASSIGNON	Changing concepts in inflammatory eye diseases A ABU EL ASRAR, CP HERBERT	FP: Neuro-ophthalmology P AYDIN, P MCGTERRIC
14:00 - 15:30	Functional imaging of the retina R BERNARDES	Corneal nerves and dry eyes L MÜLLER	FP: Physiology / Biochemistry / Pharmacology 3 I OBROSOVA, A BRON	FRO 2 MJ TASSIGNON	Immunomodulatory therapy in ocular inflammatory diseases — AD DICK	FP: Anatomy/Cell Biology 1 - Posterior Segment H UUSTALO
15:45 - 16:30	Ophthalmic Research Lecture : The Spark of Life? A Fundamental Role for Electric Fields in Guiding Cell Behaviour — John FORRESTER					in Fenix III
16:30 - 17:30	Poster Session: Cornea / Ocular Surface, Anatomy / Cell Biology, Neuro-ophthalmology / Strabismology, Physiology / Biochemistry / Pharmacology					in Neptuno
17:30 - 19:00	Emerging AMD therapies and novel administration techniques — J CUNHA-VAZ	FP: Cornea 1 - Keratoconus and corneal transplantation — PL DIGHERO, BD DUCHESNE	Neuro-ophthalmic emergencies A KAWASAKI, FX BORRUAT	Novel Ophthalmic Technologies III T MISSOTTEN	Paediatric Uveitis ; progress in its appraisal and management — B BODAGHI, CP HERBERT	FP: Anatomy/Cell Biology 2 - Anterior Segment & Adnexa — E KNOP, F VAN DER WERF
<b>Friday 7 October 2005</b>						
08:30 - 10:00	FP: Molecular Biology / Genetics / Epidemiology 2 J JACKSON, J BAILEY	Posterior capsular opacification A GALAND, RI BARRAQUER	Intravitreal use of steroids M KARACORLU, JB JONAS	OOG 1 Pathology/Oncology L DESJARDINS, E MIDENA	FP: Cornea 2 - Inflammation / Dry Eye Ph KESTELYN, J BENITEZ-DEL-CASTILLO	Workshop: Mouse model and phenotypes J GRAW
10:15 - 10:55	Keynote Lecture: The Cause and Prevention of Nuclear Cataracts: Oxygen and the Vitreous Body — David BEEBE					in Fenix III
11:00 - 12:30	Workshop: Epidemiology techniques SM SAW	FP: Glaucoma 1 - Diagnosis T ZEYEN, A BRON	Physiopathology based treatment of macular oedema — C POURNAPAS	OOG 2 Pathology/Oncology MJ JAGER, J PEER	FP: Cornea 3 - Corneal and Ocular Surface Regeneration — HS DUA, A BEHRENS	Implications of oxidative stress in the genesis of cataracts — SD VARMA, P SÖDERBERG
14:00 - 15:30	Emotion and cognition in vision: Neural mechanisms involved and related clinical conditions — A SAHRAN	FP: Glaucoma 2 - Therapy AGP KONSTAS, RI BARRAQUER	Ophthalmic blood flow regulation & prostaglandins — JO HAEFLIGER, C POURNAPAS	OOG 3 Pathology/Oncology MA SAORNIL ALVAREZ, T HADJISTILANO	FP: Cornea 4 - Refractive Surgery and Contact Lenses — L MÜLLER, J GICQUEL	Pathogenesis and prevention of diabetic cataract K HEGDE, SD VARMA
15:45 - 16:30	Keynote Lecture: Assessment of vision - Monitoring impairments and predicting functional abilities — Ian BAILEY					in Fenix III
16:30 - 17:30	Poster Session: Glaucoma, Lens and Cataract, Molecular Biology / Genetics / Epidemiology, Pathology / Oncology					in Neptuno
17:30 - 19:00	Workshop: The assessment of visual functions in people with sight loss — J BAILEY, J JACKSON	Advancements in the medical management of glaucoma — AGP KONSTAS	FP: Retina 1 - Antiangiogenic treatments T ADAMIS, HT AGOSTINI	OOG 4 E MIDENA, L DESJARDINS	FP: Lens and Cataract 1 - Clinical J GRAW, P SÖDERBERG	Workshop: Measurement of accommodation A GLASSER, R MICHAEL
19:00 - 19:30	Business meetings of the scientific sections					
<b>Saturday 8 October 2005</b>						
08:30 - 10:00	Keratoprosthesis I C LIU	Intraocular pressure and corneal thickness V DAYANIR	FP: Retina 2 - Macular pigments - Gene expression — D PAULKEHOFF	FP: Retina 3 - Diagnostic techniques C RIVA, JJ DE LAEY	Biopsy of intraocular tumours E MIDENA, JU PRAUSE	ARVO session - Successfully Conducting International Research — S ATHERTON
10:15 - 10:55	Keynote Lecture : Medical Therapy of Glaucoma in the Future: From Cell Culture to Clinic — Paul L KAUFMAN	Beyond IOP - Vascular aspects of glaucoma J STALMAANS	FP: Retina 4 - PDT - Triamcinolone C POURNAPAS, A AUGUSTIN	ISCEV C BARBER	New concepts in ocular & adnexal lymphoma M SAORNIL ALVAREZ, R VAN GINDERDEUREN	FP: Immunology / Microbiology 1 - Clinical & Experimental uveitis — U PLEYER, T MISSOTTEN
11:00 - 12:30	Keratoprosthesis II C LIU	Ocular Biomechanics K KOTLIAR	FP: Retina 5 - Diabetic Retinopathy J CUNHA-VAZ, F BANDELLO	Doctor I can't see in the dark J BARBUR, G HOLDER	FP: Pathology / Oncology S HEEGAARD, R VAN GINDERDEUREN	FP: Immunology / Microbiology 2 B BODAGHI
14:00 - 15:30	Poster Session: Retina, Vision Sciences / Electrophysiology / Physiol. Optic, Immunology / Microbiology					in Neptuno
15:30 - 16:30	EVER General Assembly and Prize Giving					in Fenix III
16:45 - 17:30	Ocular Toxoplasmosis C PAVESIO, U PLEYER	Excimer Laser Trabectulotomy (ELT) M PACHE, U GIEBS	All you want know about the macular pigment T TJM BERENDSCHOT, D VAN NORREN	FP: Vision Sciences G HOLDER, W SPILLEERS	EURETINA : Update on therapies for AMD G RICHARD	FP: Cornea 5 - Experimental and animal studies J GICQUEL, R BEJANI
20:00 - 22:00	EVER Farewell Dinner					in Marimotel